var title_f7_32_7680="Candida denture stomatitis";
var content_f7_32_7680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candida denture stomatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In patients with dentures, candida stomatitis frequently causes erythematous lesions on the hard palate without pseudomembranes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth Shay, DDS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_32_7680=[""].join("\n");
var outline_f7_32_7680=null;
var title_f7_32_7681="Flag sign in malnutrition";
var content_f7_32_7681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flag sign in the hair of a child recovering from malnutrition",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The flag sign in the hair of a child recovering from Kwashiorkor. The picture was made at INCAP in Guatemala and used as a clinical standard for examiners in international nutrition surveys.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Interdepartmental Committee on Nutrition for National Defense (1963). Manual for Nutrition Surveys 2nd ed. Department of Health, Education and Welfare, Public Health Service, NIH, US Government Printing Office, Washington DC 1963.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_32_7681=[""].join("\n");
var outline_f7_32_7681=null;
var title_f7_32_7682="Patient information: High blood pressure and pregnancy (The Basics)";
var content_f7_32_7682=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/1/37907\">",
"         Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/40/23171\">",
"         Patient information: Medicines for high blood pressure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/53/28498\">",
"         Patient information: Preeclampsia (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/54/33635\">",
"         Patient information: High blood pressure in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/58/40867\">",
"         Patient information: Preeclampsia (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: High blood pressure and pregnancy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/high-blood-pressure-and-pregnancy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7861109\">",
"      <span class=\"h1\">",
"       Can women with high blood pressure have a normal pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Most women with high blood pressure will have a normal pregnancy. But women with high blood pressure have a higher chance of having certain problems during pregnancy, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Preeclampsia &ndash; Women with preeclampsia have high blood pressure and too much protein in their urine. Preeclampsia usually happens during the second half of pregnancy, and can be a dangerous condition. It can cause problems with a baby&rsquo;s growth in the mother&rsquo;s uterus. It can also affect the mother&rsquo;s liver, kidneys, blood, heart, and nervous system.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Placental abruption &ndash; The placenta is the organ inside the uterus that brings the baby nutrients and oxygen, and carries away waste. It is attached to the inside wall of the uterus. A placental abruption is when part or all of the placenta separates from the uterus before the baby is born. If this happens, the baby might not get enough nutrients and oxygen.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Slowed growth of the baby &ndash; The baby can be small and not grow normally.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7861124\">",
"      <span class=\"h1\">",
"       What should I do before trying to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before you try to get pregnant, talk with your doctor. He or she will work with you to get your blood pressure under control. If you are taking blood pressure medicines, this might involve changing your dose or switching to a different medicine. Your doctor will also make sure that your blood pressure medicine is safe to take during pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7861139\">",
"      <span class=\"h1\">",
"       Will I have tests during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. At each visit, the doctor or nurse will check your blood pressure and your baby&rsquo;s growth. You will also have tests to check your baby&rsquo;s health at different times during pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7861154\">",
"      <span class=\"h1\">",
"       Will I need to take blood pressure medicine during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You will most likely need to take medicine during pregnancy to keep your blood pressure under control.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7861169\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse right away if:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        You don&rsquo;t feel your baby move as much as usual.",
"       </li>",
"       <li>",
"        You start having contractions. A contraction is when the uterus muscle squeezes. This can cause pain and make your belly hard.",
"       </li>",
"       <li>",
"        You have belly pain.",
"       </li>",
"       <li>",
"        You have bleeding from the vagina.",
"       </li>",
"       <li>",
"        You have any symptoms of preeclampsia. These can include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        A bad headache",
"       </li>",
"       <li>",
"        Changes in vision, such as blurry vision or flashes of lights",
"       </li>",
"       <li>",
"        Pain in the upper belly",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Swelling of the face and hands",
"       </li>",
"       <li>",
"        Sudden weight gain (more than 2 pounds in a week)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7861184\">",
"      <span class=\"h1\">",
"       Can I have a normal vaginal delivery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Most women can have a normal vaginal delivery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7861198\">",
"      <span class=\"h1\">",
"       Will my baby be healthy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your blood pressure was under control during pregnancy, chances are good that your baby will be healthy. But women with high blood pressure are more likely to give birth to their baby earlier than normal. That&rsquo;s because if you have preeclampsia, a placental abruption, or a baby that is small for its age, the doctor might need to deliver your baby early.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7861213\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/40/23171?source=see_link\">",
"       Patient information: Medicines for high blood pressure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/53/28498?source=see_link\">",
"       Patient information: Preeclampsia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=see_link\">",
"       Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"       Patient information: High blood pressure in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=see_link\">",
"       Patient information: Preeclampsia (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/32/7682?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16893 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-197.136.42.3-858ECED34C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_32_7682=[""].join("\n");
var outline_f7_32_7682=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7861109\">",
"      Can women with high blood pressure have a normal pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7861124\">",
"      What should I do before trying to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7861139\">",
"      Will I have tests during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7861154\">",
"      Will I need to take blood pressure medicine during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7861169\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7861184\">",
"      Can I have a normal vaginal delivery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7861198\">",
"      Will my baby be healthy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7861213\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=related_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/40/23171?source=related_link\">",
"      Patient information: Medicines for high blood pressure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=related_link\">",
"      Patient information: Preeclampsia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/53/28498?source=related_link\">",
"      Patient information: Preeclampsia (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_32_7683="Tumor bleeding 15c";
var content_f7_32_7683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Right hypogastric angiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 492px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right hypogastric angiogram after embolization of the cervicovaginal artery. There is occlusion of the right cervicovaginal artery (arrow) preventing filling of the tumor vessels. Vaginal bleeding stopped immediately following embolization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_32_7683=[""].join("\n");
var outline_f7_32_7683=null;
var title_f7_32_7684="Patient information: Systolic heart failure (The Basics)";
var content_f7_32_7684=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86147\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/63/20474\">",
"         Heart failure action plan - page 1",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/48/32522\">",
"          Heart failure action plan - page 2",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/15/1268\">",
"           Heart attack symptoms",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_table\" href=\"UTD.htm?1/41/1691\">",
"            What do labels about sodium mean?",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/53/35667\">",
"         Patient information: Cardiac catheterization (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/34/37410\">",
"         Patient information: Cardiac resynchronization therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/40/13956\">",
"         Patient information: Diastolic heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/5/92\">",
"         Patient information: Heart transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/41/36499\">",
"         Patient information: Medicines for heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/46/6883\">",
"         Patient information: Shortness of breath (dyspnea) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/42/21155\">",
"         Patient information: Swelling (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/53/32594\">",
"         Patient information: Edema (swelling) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/16/40195\">",
"         Patient information: Heart attack (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/36/26179\">",
"         Patient information: Heart transplantation (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/50/28450\">",
"         Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Systolic heart failure (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H284585511\">",
"      <span class=\"h1\">",
"       What is systolic heart failure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Systolic heart failure is a type of heart failure. Heart failure is a condition in which the heart does not pump well. As a result, the heart lags behind in its job of moving blood throughout the body. This can lead to symptoms such as swelling, trouble breathing, and feeling tired.",
"     </p>",
"     <p>",
"      There are 2 main types of heart failure:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        In",
"        <strong>",
"         systolic heart failure",
"        </strong>",
"        , the heart is too weak. When the heart pumps, it doesn&rsquo;t squeeze normally.",
"       </li>",
"       <li>",
"        In",
"        <strong>",
"         diastolic heart failure",
"        </strong>",
"        , the heart is too stiff. When the heart pumps, it doesn&rsquo;t relax and fill with blood normally.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These differences affect how much the heart squeezes with each heartbeat. With each squeeze, the heart pumps blood forward out of the heart. The amount of the blood in the heart that is pumped out of the heart with each heartbeat is called the &ldquo;ejection fraction&rdquo; (also called the &ldquo;EF&rdquo;). People with systolic heart failure have an ejection fraction that is lower than normal. People with diastolic heart failure have a normal ejection fraction.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H284585526\">",
"      <span class=\"h1\">",
"       What are the symptoms of systolic heart failure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble breathing &ndash; At first, people might trouble breathing only with activity. Over time, they can also have trouble breathing when resting or lying down.",
"       </li>",
"       <li>",
"        Swelling in the feet, ankles, legs, or belly",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H284585541\">",
"      <span class=\"h1\">",
"       Is there a test for systolic heart failure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse thinks you might have this condition, he or she will order some of the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Chest X-ray &ndash; This test can show if there is fluid in the lungs. It also shows the general shape of the heart and large blood vessels in the chest.",
"       </li>",
"       <li>",
"        Electrocardiogram (also called &ldquo;ECG&rdquo; or &ldquo;EKG&rdquo;) &ndash; This test measures the electrical activity in the heart.",
"       </li>",
"       <li>",
"        Echocardiogram (also called an &ldquo;echo&rdquo;) &ndash; This test uses sound waves to create a picture of the heart as it beats.",
"       </li>",
"       <li>",
"        Stress test &ndash; During this test, a doctor records your ECG while you exercise on a treadmill or bike, or get medicine to make your heart pump faster.",
"       </li>",
"       <li>",
"        Cardiac catheterization (also known as &ldquo;cardiac cath&rdquo;) &ndash; During this test, a doctor puts a thin tube into a blood vessel in your leg and threads it up to your heart. When the tube is in place, he or she can do tests or unblock a clogged artery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H284585556\">",
"      <span class=\"h1\">",
"       How is systolic heart failure treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment usually includes:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Taking medicines &ndash; Medicines can help reduce symptoms and help you live longer. They might also lower the chance that you will need to go to the hospital. Many people need to take 3 or more medicines every day. The right ones for you will depend on your symptoms and other medical conditions, and can include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        An angiotensin-converting enzyme inhibitor (called an &ldquo;ACE inhibitor&rdquo;) &ndash; This medicine can relax blood vessels and make it easier for the heart to pump. It sometimes lowers blood pressure. If you can&rsquo;t take an ACE inhibitor, your doctor might prescribe an angiotensin receptor blocker (called an &ldquo;ARB&rdquo;) or other medicines.",
"       </li>",
"       <li>",
"        A beta-blocker &ndash; This medicine can slow the heart rate down and sometimes lowers blood pressure. It can reduce the amount of work the heart has to do. When you start taking a beta-blocker, you might feel a little worse. But after your body gets used to the medicine, you might start to feel better.",
"       </li>",
"       <li>",
"        A diuretic (water pill) &ndash; This medicine helps the body get rid of extra salt and fluid. It can reduce the fluid in your lungs or swelling in your legs or belly.",
"       </li>",
"       <li>",
"        An aldosterone receptor antagonist &ndash; This is similar to a diuretic. It helps the body get rid of extra salt and fluid. But it also helps the body hold onto a mineral called potassium. That&rsquo;s important, because the body needs potassium to work normally. Other diuretics sometimes make the body lose potassium.",
"        <br/>",
"        <br/>",
"        It&rsquo;s important to take your medicines every day, even if you feel well. Tell your doctor or nurse if you can&rsquo;t afford your medicines or if they cause side effects. There are often ways to help with these issues.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Eating a low-salt (low-sodium) diet &ndash; Cutting down on salt can help reduce your symptoms. Avoid adding salt to your food at the table or when you cook. Also, avoid foods that come in boxes and cans, unless their labels say they are low in sodium (",
"        <a class=\"graphic graphic_table graphicRef61514 \" href=\"UTD.htm?1/41/1691\">",
"         table 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Treating your coronary heart disease (if you have it) &ndash; In coronary heart disease, the arteries that supply blood to the heart get clogged. Treatment can include medicines, a procedure to unblock a clogged artery, or surgery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other treatment for systolic heart failure sometimes includes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A device to help the heart pump with more force or beat at the right rhythm",
"       </li>",
"       <li>",
"        A pump attached to the heart to increase blood flow to the body and reduce the work the heart needs to do",
"       </li>",
"       <li>",
"        Heart transplant surgery &ndash; This is surgery to replace your diseased heart with a healthy heart. It is done only when all other treatments do not work.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H284585604\">",
"      <span class=\"h1\">",
"       What else can I do on my own to protect my heart?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help feel better and reduce the chances that you will need to go to the hospital, you can do the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Call your doctor or nurse if you are dizzy or weak, or if you lose or gain weight suddenly. Weigh yourself every morning after you urinate but before breakfast. Call your doctor or nurse if your weight goes up by 2 or more pounds (1 kilogram) in 1 day, or 4 or more pounds (2 kilograms) in 1 week.",
"       </li>",
"       <li>",
"        Follow the action plan your doctor gives you. An action plan is a list of instructions that tells you what to do if your symptoms change. To use an action plan, watch your symptoms closely and weigh yourself every day. If you do not feel well or if you lose or gain weight suddenly, look at your action plan to see what to do (",
"        <a class=\"graphic graphic_figure graphicRef72459 \" href=\"UTD.htm?19/63/20474\">",
"         figure 1",
"        </a>",
"        and",
"        <a class=\"graphic graphic_figure graphicRef75501 \" href=\"UTD.htm?31/48/32522\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Call 9-1-1 if you have chest pain or other signs of a heart attack (",
"        <a class=\"graphic graphic_figure graphicRef52579 \" href=\"UTD.htm?1/15/1268\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Lose weight, if you are overweight.",
"       </li>",
"       <li>",
"        Stop smoking.",
"       </li>",
"       <li>",
"        Limit the amount of alcohol you drink. If you are a woman, do not have more than 1 drink a day. If you are a man, do not have more than 2.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H284585619\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36499?source=see_link\">",
"       Patient information: Medicines for heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13956?source=see_link\">",
"       Patient information: Diastolic heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=see_link\">",
"       Patient information: Swelling (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=see_link\">",
"       Patient information: Cardiac catheterization (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/34/37410?source=see_link\">",
"       Patient information: Cardiac resynchronization therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/5/92?source=see_link\">",
"       Patient information: Heart transplant (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/53/32594?source=see_link\">",
"       Patient information: Edema (swelling) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28450?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"       Patient information: Heart attack (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=see_link\">",
"       Patient information: Heart transplantation (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/32/7684?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86147 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-210.101.131.231-4F3FA9F29D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_32_7684=[""].join("\n");
var outline_f7_32_7684=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H284585511\">",
"      What is systolic heart failure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H284585526\">",
"      What are the symptoms of systolic heart failure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H284585541\">",
"      Is there a test for systolic heart failure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H284585556\">",
"      How is systolic heart failure treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H284585604\">",
"      What else can I do on my own to protect my heart?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H284585619\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86147\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/63/20474\">",
"      Heart failure action plan - page 1",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/48/32522\">",
"       Heart failure action plan - page 2",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/15/1268\">",
"        Heart attack symptoms",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?1/41/1691\">",
"         What do labels about sodium mean?",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=related_link\">",
"      Patient information: Cardiac catheterization (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/34/37410?source=related_link\">",
"      Patient information: Cardiac resynchronization therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13956?source=related_link\">",
"      Patient information: Diastolic heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/53/32594?source=related_link\">",
"      Patient information: Edema (swelling) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/5/92?source=related_link\">",
"      Patient information: Heart transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=related_link\">",
"      Patient information: Heart transplantation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36499?source=related_link\">",
"      Patient information: Medicines for heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28450?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=related_link\">",
"      Patient information: Swelling (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_32_7685="Tofacitinib: Patient drug information";
var content_f7_32_7685=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tofacitinib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/49/18198?source=see_link\">",
"     see \"Tofacitinib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15673699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xeljanz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F15962375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700828",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       TB (tuberculosis) has been seen in patients started on this drug. These patients were exposed to TB in the past, but never got the infection. You will be tested to see if you have been exposed to TB before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may add to your chance of getting lymphoma or other cancers.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have happened in patients who take this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15962377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat rheumatoid arthritis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15962376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4100698",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tofacitinib or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15962381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hepatitis B testing may be done. A hepatitis B infection may get worse during care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have been reported with use of this drug. If you have any infection, are taking antibiotics now or in the recent past, or have many infections, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have stomach ulcers, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15962382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15962383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15962379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698578",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will need a TB (tuberculosis) test before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15962380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15962384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15962385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87670 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-93025ABAAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_32_7685=[""].join("\n");
var outline_f7_32_7685=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673699\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962375\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962377\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962376\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962381\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962382\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962383\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962379\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962380\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962384\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962385\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/49/18198?source=related_link\">",
"      Tofacitinib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_32_7686="Active trachoma inflam";
var content_f7_32_7686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Active trachoma: inflammation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Normal eyelid. Deep tarsal vessels (arrow). B) WHO grade TI (trachomatous inflammation, intense). To make a diagnosis of TI, papillary hypertrophy and inflammatory thickening of the upper tarsal conjunctiva must obscure more than half the deep tarsal vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_32_7686=[""].join("\n");
var outline_f7_32_7686=null;
var title_f7_32_7687="Amitriptyline: Pediatric drug information";
var content_f7_32_7687=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amitriptyline: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"    see \"Amitriptyline: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/17/32021?source=see_link\">",
"    see \"Amitriptyline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bio-Amitriptyline;",
"     </li>",
"     <li>",
"      Dom-Amitriptyline;",
"     </li>",
"     <li>",
"      Elavil;",
"     </li>",
"     <li>",
"      Levate&reg;;",
"     </li>",
"     <li>",
"      Novo-Triptyn;",
"     </li>",
"     <li>",
"      PMS-Amitriptyline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Tricyclic (Tertiary Amine)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimigraine Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"      see \"Amitriptyline: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chronic pain management: Children: Initial: 0.1 mg/kg at bedtime, may advance as tolerated over 2-3 weeks to 0.5-2 mg/kg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Depressive disorders:",
"     <b>",
"      Note:",
"     </b>",
"     Not FDA approved for use in pediatric patients; controlled clinical trials have not shown tricyclic antidepressants to be superior to placebo for the treatment of depression in children and adolescents (Dopheide, 2006; Wagner, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Investigationally initial doses of 1 mg/kg/day given in 3 divided doses with increases to 1.5 mg/kg/day have been reported in a small number of children (n=9) 9-12 years of age; clinically, doses up to 3 mg/kg/day (5 mg/kg/day if monitored closely) have been proposed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: Initial: 25-50 mg/day; may give in divided doses; increase gradually to 100 mg/day in divided doses; maximum dose: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Migraine prophylaxis: Children: Limited studies exist; one small study (n=24; mean age: 8 years; range: 6-12 years) used increasing doses over 5 days to reach a final dose of 1.5 mg/kg/day; effectiveness was seen in 19 of 24 patients, but 5 children dropped out of the trial due to adverse effects (Sorge, 1982). A recent large open-label trial in 192 children (mean age 12 &plusmn; 3 years) with &gt;3 headaches/month (61% with migraine, 8% with migraine with aura, and 10% with tension-type headaches) used an initial dose of 0.25 mg/kg/day given before bedtime; doses were increased every 2 weeks by 0.25 mg/kg/day to a final dose of 1 mg/kg/day; patients also used appropriate abortive medications and lifestyle adjustments; at initial re-evaluation (mean: 67 days after initiation of therapy), the mean number of headaches per month significantly decreased from 17.1 to 9.2; the mean duration of headaches decreased from 11.5 to 6.3 hours; continued improvement was observed at follow-up visits; minimal adverse effects were reported.",
"     <b>",
"      Note:",
"     </b>",
"     Mean final dose was 0.99 &plusmn; 0.23 mg/kg; range: 0.16-1.7 mg/kg/day; ECGs were obtained on children receiving &gt;1 mg/kg/day or in those describing a cardiac side effect (Hershey, 2000). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Depression: Adults: Initial: 50-100 mg/day single dose at bedtime or in divided doses; dose may be gradually increased up to 300 mg/day; once symptoms are controlled, decrease gradually to lowest effective dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F133713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F133696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088622.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088622.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral: May administer with food to decrease GI upset",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of various forms of depression, often in conjunction with psychotherapy; analgesic for certain chronic and neuropathic pain; migraine prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F133796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amitriptyline may be confused with aminophylline, imipramine, nortriptyline",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Elavil&reg; may be confused with Aldoril&reg;, Eldepryl&reg;, enalapril, Equanil&reg;, Plavix&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [moderate for SIADH]; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F133793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anticholinergic effects may be pronounced; moderate to marked sedation can occur (tolerance to these effects usually occurs).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, AV conduction changes, cardiomyopathy (rare), ECG changes (nonspecific), heart block, hypertension, MI, orthostatic hypotension, palpitation, stroke, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, ataxia, cognitive function impaired, coma, confusion, coordination impaired, disorientation, dizziness, extrapyramidal symptoms, fatigue, hallucinations, headache, hyperpyrexia, insomnia, nightmares, restlessness, sedation, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Allergic rash, alopecia, photosensitivity, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Syndrome of inappropriate ADH secretion (SIADH)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, black tongue, constipation, diarrhea, nausea, paralytic ileus, peculiar taste, stomatitis, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bone marrow depression, eosinophilia, purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness, paresthesia, peripheral neuropathy, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, mydriasis, ocular pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, withdrawal reactions (nausea, headache, malaise)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Neuroleptic malignant syndrome (rare), serotonin syndrome (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amitriptyline (cross-sensitivity with other tricyclics may occur) or any component; narrow-angle glaucoma; use of MAO inhibitors within 14 days (potentially fatal reactions may occur); concurrent use of cisapride; use during acute recovery phase after MI",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiac conduction disturbances, cardiovascular disease, seizure disorders, diabetes mellitus, narrow-angle glaucoma, increased intraocular pressure, history of urinary retention or bowel obstruction, hepatic or renal dysfunction, hyperthyroidism or those receiving thyroid hormone replacement; degree of sedation, anticholinergic effects, and risk of orthostatic hypotension are very high relative to other antidepressants; manufacturer does not recommend use in children &lt;12 years of age",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amitriptyline is not approved for use in pediatric patients. Clinical worsening of depression or suicidal ideation and behavior may occur in children and adults with major depressive disorder",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In clinical trials, antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. This risk must be considered before prescribing antidepressants for any clinical use. Short-term studies did",
"     <b>",
"      not",
"     </b>",
"     show an increased risk of suicidality with antidepressant use in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients of all ages who are treated with antidepressants for any indication require appropriate monitoring and close observation for clinical worsening of depression, suicidality, and unusual changes in behavior, especially during the first few months after antidepressant initiation or when the dose is adjusted. Family members and caregivers should be instructed to closely observe the patient (ie, daily) and communicate condition with healthcare provider. Patients should also be monitored for associated behaviors (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania) which may increase the risk for worsening depression or suicidality. Worsening depression or emergence of suicidality (or associated behaviors listed above) that is abrupt in onset, severe, or not part of the presenting symptoms, may require discontinuation or modification of drug therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Do not discontinue abruptly in patients receiving high doses chronically (withdrawal symptoms may occur). To reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care. Screen individuals for bipolar disorder prior to treatment (using antidepressants alone may induce manic episodes in patients with this condition). May worsen psychosis in some patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F133781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP2E1 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F133705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Amitriptyline may enhance the arrhythmogenic effect of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1051003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Riboflavin dietary requirements may be increased; increased dietary fiber may decrease drug effect",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F133708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F133724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal studies. Amitriptyline crosses the human placenta; CNS effects, limb deformities and developmental delay have been noted in case reports.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, mental status, weight. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1050994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Plasma levels do not always correlate with clinical effectiveness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amitriptyline plus nortriptyline (active metabolite): 100-250 ng/mL (SI: 360-900 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nortriptyline 50-150 ng/mL (SI: 190-570 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: &gt;500 ng/mL (SI: &gt;1800 nmol/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the synaptic concentration of serotonin and/or norepinephrine in the CNS by inhibition of their reuptake by the presynaptic neuronal membrane",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1050998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Therapeutic antidepressant effects begin in 7-21 days; maximum effects may not occur for &ge;2 weeks and as long as 4-6 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid, well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses placenta; enters breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to nortriptyline (active), hydroxy derivatives and conjugated derivatives",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, adults: 9-25 hours (15-hour average)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renal excretion of 18% as unchanged drug; small amounts eliminated in feces by bile",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Nondialyzable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/17/32021?source=see_link\">",
"      see \"Amitriptyline: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of amitriptyline. An increased risk of suicidal thinking and behavior has been reported with the use of antidepressants in children, adolescents, and young adults (18-24 years of age). Notify physician if you feel more depressed, have thoughts of suicide, or become more agitated or irritable. Avoid alcohol and the herbal medicine St John's wort; limit caffeine intake; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; do not discontinue abruptly; may discolor urine to a blue-green color. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to promotion of weight gain with amitriptyline, other antidepressants (ie, imipramine or desipramine) may be preferred in heavy or obese children and adolescents",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA, \"Recognizing and Treating Depression in Children and Adolescents,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2006, 63(3):233-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/32/7687/abstract-text/16434782 /pubmed\" id=\"16434782 \" target=\"_blank\">",
"        16434782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Elser JM and Woody RC, &ldquo;Migraine Headache in the Infant and Young Child,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 1990, 30(6):366-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/32/7687/abstract-text/2370139/pubmed\" id=\"2370139\" target=\"_blank\">",
"        2370139",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hershey AD, Powers SW, Bentti AL, et al, &ldquo;Effectiveness of Amitriptyline in the Prophylactic Management of Childhood Headaches,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 2000, 40(7):539-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/32/7687/abstract-text/10940092/pubmed\" id=\"10940092\" target=\"_blank\">",
"        10940092",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kashani JH, Shekim WO, and Reid JC, &ldquo;Amitriptyline in Children With Major Depressive Disorder: A Double-Blind Crossover Pilot Study,&rdquo;",
"      <i>",
"       J Am Acad Child Psychiatry",
"      </i>",
"      , 1984, 23(3):348-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/32/7687/abstract-text/6736501/pubmed\" id=\"6736501\" target=\"_blank\">",
"        6736501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy HB, Harper CR, and Weinberg WA, &ldquo;A Practical Approach to Children Failing in School,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1992, 39(4):895-928.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/32/7687/abstract-text/1635811/pubmed\" id=\"1635811\" target=\"_blank\">",
"        1635811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sorge F, Barone P, Steardo L, et al, &ldquo;Amitriptyline as a Prophylactic for Migraine in Children,&rdquo;",
"      <i>",
"       Acta Neurol (Napoli)",
"      </i>",
"      , 1982, 4(5):362-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/32/7687/abstract-text/7158453/pubmed\" id=\"7158453\" target=\"_blank\">",
"        7158453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner KD, \"Pharmacotherapy for Major Depression in Children and Adolescents,\"",
"      <i>",
"       Prog Neuropsychopharmacol Biol Psychiatry",
"      </i>",
"      , 2005, 29(5):819-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/32/7687/abstract-text/15908090/pubmed\" id=\"15908090\" target=\"_blank\">",
"        15908090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12598 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_32_7687=[""].join("\n");
var outline_f7_32_7687=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708615\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133739\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050991\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050984\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133713\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133696\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874280\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050996\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050995\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133796\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133793\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051000\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050983\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050982\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133781\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133705\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051003\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133708\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133724\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050990\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050994\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050981\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050998\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050999\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050989\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051001\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12598\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12598|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=related_link\">",
"      Amitriptyline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/17/32021?source=related_link\">",
"      Amitriptyline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_32_7688="Microbiology and pathobiology of Neisseria meningitidis";
var content_f7_32_7688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology and pathobiology of Neisseria meningitidis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/32/7688/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/32/7688/contributors\">",
"     Michael Apicella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/32/7688/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/32/7688/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/32/7688/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/32/7688/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/32/7688/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/32/7688/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with Neisseria meningitidis can produce a variety of clinical manifestations, ranging from transient fever and bacteremia to fulminant disease with death ensuing within hours of the onset of clinical symptoms. N. meningitidis is a common cause of community-acquired bacterial meningitis in both children and adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Causative organisms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology of bacterial meningitis in adults\", section on 'Community-acquired'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mortality can be very high in patients with meningococcal disease if the infection is not treated appropriately, and long-term sequelae can be severe even in successfully managed cases due primarily to difficulty in managing the endotoxin-induced vascular collapse frequently induced by this organism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The microbiology and pathobiology of N. meningitidis will be reviewed here. The epidemiology, clinical features, diagnosis, treatment, and prevention of meningococcal infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link\">",
"     \"Epidemiology of Neisseria meningitidis infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=see_link\">",
"     \"Clinical manifestations of meningococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27285?source=see_link\">",
"     \"Diagnosis of meningococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link\">",
"     \"Treatment and prevention of meningococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link\">",
"     \"Meningococcal vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningococcal disease was first described in 1805 after an epidemic of meningitis in Geneva. It was not until 1882 that the pathogen responsible for this disease was first isolated from the cerebrospinal fluid (CSF) of an infected patient. The fact that the organism could be carried in the nasopharynx of healthy individuals was first recognized in 1890. In 1909, immunologically distinct serotypes of the meningococcus were identified. This established the basis for serum therapy, which was instituted by Flexner in 1913 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meningococcal epidemics among military recruits were a major consequence of military mobilization. As a result, the military participated in a number of important studies dealing with meningococcal disease, including the development of chemoprophylactic and immunologic methods to prevent infection. During World War I, the British army recognized that the frequency of carriage of the case strain rose prior to and during epidemics. With the advent of sulfonamides as an early antimicrobial treatment for meningococcal disease, the United States army used chemoprophylaxis with sulfonamides to dramatically reduce the incidence of disease among recruits during World War II. After the war, the availability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    greatly improved the treatment of meningococcal meningitis and sepsis, resulting in a substantial drop in mortality rates.",
"   </p>",
"   <p>",
"    In 1963, the first reports of resistance to sulfonamides appeared at Fort Ord, California, among military recruits. Nasopharyngeal carriage could no longer be controlled with sulfonamides. During the Vietnam War, the incidence of meningococcal infection at some of the recruit training centers reached epidemic levels. The United States military continued to pursue chemoprophylaxis, which led to the identification of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    as effective agents. The United States Army also played a major role in the development of the meningococcal capsular polysaccharide vaccine, which was successful in preventing meningococcal disease in vaccinated recruits [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link\">",
"     \"Meningococcal vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;N. meningitidis is a gram-negative diplococcus approximately 0.7 to 1 micron in diameter. The adjacent sides are somewhat flattened. The organism is aerobic or facultatively anaerobic. When grown anaerobically, it requires nitrite as an electron acceptor. The meningococcus produces an oxidase that will oxidize the colorless dye tetramethyl-p-phenylenediamine to a bright purple color. This oxidase test has been used in the initial identification of the organism.",
"   </p>",
"   <p>",
"    The meningococcus can use both glucose and maltose; oxidative metabolism of these sugars produces an acid. The shift in pH caused by this reaction has been traditionally used to differentiate meningococci from gonococci, which fail to oxidize maltose.",
"   </p>",
"   <p>",
"    Meningococci can be subdivided into serogroups based upon distinct capsular polysaccharides; eight serogroups most commonly cause infections in humans (A, B, C, X, Y, Z, W135, and L). The complete genome of several strains of serogroup B and one strain of serogroup A N. meningitidis have been sequenced; a number of genes were found to undergo phase variation in serogroup B, which may partially explain why this serogroup is the most successful at eluding immune recognition by the host [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of transposon mutagenesis has identified 73 genes in serogroup B N. meningitidis that are essential for maintaining bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/4\">",
"     4",
"    </a>",
"    ]. This is an important issue since establishment and maintenance of bacteremic disease is required for all of the pathologic sequelae of meningococcal infection.",
"   </p>",
"   <p>",
"    The meningococcus is considered a fastidious organism. Successful isolation from clinical sites such as blood and CSF necessitates care in handling the sample. The organism is highly susceptible to cold, high pH, and drying; as a result, specimens must be processed quickly.",
"   </p>",
"   <p>",
"    Samples from normally sterile sites should be inoculated on nonselective enriched media, such as chocolate agar, and incubated in a moist environment at 37&ordm;C under an atmosphere of 3 to 10 percent CO2. Selective media such as Thayer-Martin can enhance the isolation of the meningococcus from sites colonized by other bacteria such as the pharynx. This media contains antibiotics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    , which do not inhibit the growth of the meningococcus but prevent growth of other gram-negative bacteria, gram-positive bacteria, and yeast.",
"   </p>",
"   <p>",
"    Because the outcome of meningococcal infection is related to the rapidity with which antimicrobial and supportive therapy is initiated, a number of approaches have been taken to decrease the time to diagnosis. The use of specific anticapsular antisera in coagglutination systems has been used successfully in the early identification of N. meningitidis infection of the CSF. PCR can also identify N. meningitidis in clinical samples [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;N. meningitidis exclusively infects humans. The pathobiology of meningococcal infection is related to both nasopharyngeal colonization and a variety of virulence factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nasopharyngeal carriage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonization of the nasopharyngeal surface by N. meningitidis is a prerequisite for the development of systemic infection. The only exceptions are the rare occurrences in which N. meningitidis is accidentally inoculated parenterally either in the laboratory or in the clinical setting.",
"   </p>",
"   <p>",
"    Colonization of the nasopharynx occurs by inhalation of aerosolized particles containing meningococci. The nasopharynx is a mixed epithelial surface containing ciliated, secretory, and nonciliated, nonsecretory cells. Adenoids and tonsils serve as associated lymphoid tissues. These structures have mucosal surfaces that are covered with typical upper airway epithelium to which N. meningitidis can attach via adhesion proteins and then invade.",
"   </p>",
"   <p>",
"    Studies indicate that most carrier strains lack capsular production. While most meningococcal strains isolated from patients with meningococcal disease belong to a limited number of clonal types, strains isolated from carriers comprise numerous clonotypes, with a small proportion of the strains representing invasive clones [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Virulence factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;N. meningitidis uses a variety of virulence factors to adhere to and invade human epithelial and endothelial cells and to evade the human immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/7\">",
"     7",
"    </a>",
"    ]. These include phase variation, antigenic variation, and molecular mimicry of human antigens.",
"   </p>",
"   <p>",
"    The principal virulence factors that have been identified to date include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pili, also called fimbria",
"     </li>",
"     <li>",
"      Opacity proteins",
"     </li>",
"     <li>",
"      Lipooligosaccharide",
"     </li>",
"     <li>",
"      Capsular polysaccharide",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pili (fimbria)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pili of N. meningitidis are attachment organelles that undergo phase variation. The pili of pathogenic Neisseria are composed of a pilin subunit that is encoded in the expression locus. Other, incomplete copies of pilin genes are found in silent loci. The genes in the expression and silent loci undergo frequent recombinational events causing an extraordinarily high rate of variation.",
"   </p>",
"   <p>",
"    In addition to the principal pilus subunit (pilin or PilE), N. meningitidis produces low quantities of a phase-variable PilC protein that is implicated in pilus biogenesis and pilus-mediated epithelial cell adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. PilC protein, isolated from a strain of gonococcus that overproduces the protein, interacts specifically with human epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/10\">",
"     10",
"    </a>",
"    ]. Binding of purified PilC effectively competes with pilus-mediated attachment of both N. gonorrhoeae and N. meningitidis. When fluorescent beads were coated with purified pili from a piliated mutant deficient in PilC, adherence to epithelial cells was abrogated; pretreatment with purified PilC restored adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pili are posttranslationally modified by addition of either an O-linked trisaccharide, Gal (beta 1,4) Gal (alpha 1,3) 2,4-diacetamido-2,4,6-trideoxyhexose, or an O-linked disaccharide Gal (alpha 1,3) GlcNAc [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/12\">",
"     12",
"    </a>",
"    ]. Other studies indicate that phosphorylcholine posttranscriptionally modifies meningococcal pili as well [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunogold electron microscopy using antisera raised against purified PilC and synthetic peptides located PilC at the tip of gonococcal pili [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/10\">",
"     10",
"    </a>",
"    ]. The tissue receptor for the pili of pathogenic Neisseria is CD46 (also called membrane cofactor protein) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pili may trigger cell signal mechanisms within epithelial cells. As an example, purified pili from an adherent strain led to an increase in cytosolic free calcium, whereas those from a low affinity binding mutant did not [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/15\">",
"     15",
"    </a>",
"    ]. Antibodies against CD46 blocked intracellular calcium release.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Opacity proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive and colonizing isolates of N. meningitidis express one or more of a family of closely related opacity proteins, such as Opa and Opc, on their outer membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. As the organism moves closer to the cells, these proteins play a role in attachment and perhaps in defining tissue specificity of the organism [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have been performed with several variants expressing different Opa (OpaA, OpaB, OpaD) and Opc proteins with the following findings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Analysis of sequence diversity among Opa genes from hyperinvasive meningococcal strains, representing the seven most common disease-causing clonotypes, identified particular Opa variants that were consistently associated with each of the clonotypes over long time periods often spanning decades [",
"      <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/18\">",
"       18",
"      </a>",
"      ]. These observations suggest that particular Opa proteins confer fitness to invasive clonotypes and that these Opa proteins should be included in new vaccine formulations.",
"     </li>",
"     <li>",
"      Opc was the most efficient protein for increasing bacterial interaction with endothelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/19\">",
"       19",
"      </a>",
"      ]. In contrast, OpaB enhanced attachment to human epithelial cells to at least the same degree as Opc. The interaction with epithelial cells was inhibited by monoclonal antibody directed against OpaB.",
"     </li>",
"     <li>",
"      Opc can bind to heparan sulfate proteoglycans on epithelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/20\">",
"       20",
"      </a>",
"      ]. Opa28 strains that do not have Opc also bound to proteoglycans and, in contrast to Opc, to carcinoembryonic antigen (CEA) receptors. Mutants lacking both Opc and Opa28 were unable to bind to either of these receptors.",
"     </li>",
"     <li>",
"      Surface sialic acids on capsule and lipopolysaccharide (LPS) influence attachment and entry to epithelial cells. The Opc interaction with the proteoglycan receptor is decreased when sialic acid is present on the surface of the organism [",
"      <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/20\">",
"       20",
"      </a>",
"      ]. In addition, Opa-mediated interactions are significantly reduced or eliminated in mutants expressing capsule or sialylated LPS [",
"      <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Environmental factors controlling lipopolysaccharide and capsule phenotype affect the invasiveness of N. meningitidis strains. This effect may be based upon the ability to downregulate outer membrane protein mediated binding to cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Lipooligosaccharide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lipooligosaccharide (LOS) of N. meningitidis is analogous to the LPS of enteric gram negative-bacilli, although there are a number of structural differences between LOS and LPS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/21\">",
"     21",
"    </a>",
"    ]. As an example, LOS lacks the repeating O-antigen of the LPS.",
"   </p>",
"   <p>",
"    LOS is generally present on gram-negative pathogens (pathogenic Neisseria and Haemophilus, H. ducreyi, Moraxella, Campylobacter, and Bordetella) that infect non-enteric surfaces; some Campylobacter species can also affect the gastrointestinal tract. The oligosaccharide portions of LOS contain structures that mimic human tissue antigens (eg, paragloboside, pk, the i antigen, Lewis X, and sialyl-Lewis X) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some strains of pathogenic Neisseria, the LOS is the basis of resistance to complement-mediated lysis using human serum. The meningococcal LOS is serologically diverse, as at least 12 different LOS serotypes have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/23\">",
"     23",
"    </a>",
"    ]. The chemical structures of the oligosaccharide portion of all 12 LOS serotypes have been elucidated. Many of the biosynthesis genes necessary for the production of the oligosaccharide portion of the LOS have been identified and a number of mutants have been created.",
"   </p>",
"   <p>",
"    The lipid A portion of meningococcal LOS is structurally similar to the lipid A of Enterobacteriaceae LPS, which is the endotoxin moiety of these organisms. It contains the typical dihexosamine backbone structure with two phosphate head groups, and phosphoethanolamine is frequently present as a component of the head groups. Attached to the dihexosamine backbone through amide and ester linkages are four hydroxymyristic acid moieties; two of these are substituted with lauric acid at the 3 position [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The highest plasma levels of endotoxin measured in sepsis have been found in patients with meningococcemia. The ability of the organism to shed its outer membrane in bleb or vesicle-like structures is the primary factor in producing these high levels of endotoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/25\">",
"     25",
"    </a>",
"    ]. Strains of meningococcal serogroups A, B, and C release membrane blebs in the log, but not the lag, phase of growth. The release of endotoxin in the form of membrane blebs is not unique to the meningococcus. Similar mechanisms for the release of endotoxin have been documented in a number of other gram-negative bacteria including Salmonella, Shigella, Escherichia coli, Citrobacter, and Haemophilus spp. However, the degree of blebbing in these other species is considerably less than that seen with meningococcus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Capsular polysaccharides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial capsular polysaccharides are polyanionic, well-hydrated structures that provide a physical defense barrier around the bacterium and may also determine access of molecules and ions to the bacterial cell outer membrane. The capsular polysaccharides of the meningococcus are highly charged, hydrophilic structures that act as a barrier to phagocytosis or complement-mediated lysis.",
"   </p>",
"   <p>",
"    The genes for capsule production are contained within a single locus of approximately 18 kb. The locus is described as comprising three regions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/26\">",
"     26",
"    </a>",
"    ]. Regions 1 and 3 are common to all capsular types: region 1 encodes the \"common\" functions of capsule export, and region 3 probably encodes control functions. Region 2 differs among the capsule types and is responsible for encoding the functions for synthesis of the specific capsule. The common biochemical properties of these capsules and genetic organization of their production has led to their classification as type II capsules.",
"   </p>",
"   <p>",
"    Serogrouping of meningococcal strains into at least 13 serogroups is based upon the capsular polysaccharide type. The overwhelming majority of disease worldwide is caused by five serogroups: A, B, C, Y, and W135. The immunogenicity of the group A, C, Y, and W135 polysaccharides in humans appears to be a function of their molecular size. The meningococcal B capsule has an alpha 2,8-linked polysialic acid structure that is similar to human intracellular adhesion molecules (ICAMs); it is believed that it is a very poor immunogen because it is a mimic of these ICAMs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H454501268#H454501268\">",
"     \"Meningococcal vaccines\", section on 'Group B meningococcus vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Changing expression of the capsular polysaccharide appears to be important in the pathogenesis of meningococcal infection. Since the capsule acts as an antiphagocytic mechanism, its expression hinders interaction with epithelial cells. The meningococcus appears to downregulate capsular expression upon contact with epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/17,28,29\">",
"     17,28,29",
"    </a>",
"    ]. This change may facilitate colonization and entry into nasopharyngeal epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This is in contrast to the observation that capsule expression is important for meningococcal survival within human cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/30\">",
"     30",
"    </a>",
"    ]. In vitro assays suggest that unencapsulated meningococci are more susceptible to the antibacterial effects of cationic antimicrobial peptides than encapsulated meningococci. The same studies demonstrated upregulation of capsular biosynthesis genes during intracellular infection.",
"   </p>",
"   <p>",
"    In a time period coinciding with the introduction of the conjugate meningococcal vaccine, capsular switching, a mechanism by which meningococcal isolates alter the antigenic profile of their polysaccharide capsules, has been shown to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/31\">",
"     31",
"    </a>",
"    ]. There is no evidence that it has impacted the efficacy of the currently formulated vaccine, but this does require ongoing population-wide surveillance since it could result in reduced vaccine efficacy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link\">",
"     \"Meningococcal vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cell entry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon contact with epithelial cells, the meningococcus initiates cytoskeletal changes within the cell, such as cortical actin rearrangements [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/8,16\">",
"     8,16",
"    </a>",
"    ]. Adhesion mediated by pili, Opc, and OpaA can trigger these rearrangements, whereas nonadherent strains do not [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/8,16\">",
"     8,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attachment of the meningococcus to the epithelial surface is followed by a process that resembles receptor mediated endocytosis. The bacteria are incorporated into vacuoles and then transported to the basolateral surface of the cell.",
"   </p>",
"   <p>",
"    Only unencapsulated meningococci enter epithelial cells, and capsular biosynthesis ceases as the meningococcus enters such cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/29,32\">",
"     29,32",
"    </a>",
"    ]. This change is mediated at least in part by reversible inactivation of essential sialic acid biosynthesis genes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/29,32\">",
"     29,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Survival within epithelial cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors that permit survival of N. meningitidis within epithelial cells are not well understood. Type 2 IgA1 protease, produced by the meningococcus, increases degradation of lysosome associated membrane protein 1 (LAMP1), a membrane glycoprotein associated with endosomes and lysosomes; the increased degradation is mediated by the Neisseria type 2 IgA1 protease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/33\">",
"     33",
"    </a>",
"    ]. An IgA protease mutant strain that does not affect LAMP1 turnover grows poorly in epithelial cells compared to the wildtype strain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The capsule may also be important for intracellular survival of N. meningitidis, as discussed above. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Capsular polysaccharides'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Interaction with phagocytic cells and the complement system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neisseria meningitidis has important interactions with phagocytic cells and the complement system, which influence pathogenicity and host defense:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Opacity proteins influence the interaction of N. meningitidis strains with polymorphonuclear leukocytes via Opa proteins and with monocytes via Opc [",
"      <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Opacity proteins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Capsular biosynthesis ceases as the meningococcus enters epithelial cells (such as those in the nasopharynx), an effect that involves reversible inactivation of essential sialic acid biosynthesis genes. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Capsular polysaccharides'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, sialic acid expression must be downregulated for interactions with phagocytic cells to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Piliated, sialylated organisms expressing both Opa proteins and Opc, which is a common phenotype in nasopharyngeal isolates, can be internalized by phagocytes in the absence of antibody or complement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/36\">",
"     36",
"    </a>",
"    ]. In contrast, piliated, sialylated strains found in the bloodstream can adhere to epithelial cells but do not interact with phagocytic cells.",
"   </p>",
"   <p>",
"    Group B N. meningitidis, a serogroup that expresses surface sialic acid, is particularly resistant to serum-mediated and phagocytic killing and does not bind mannose-binding lectin (MBL), a serum protein that activates the classical complement pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/37\">",
"     37",
"    </a>",
"    ]. In contrast, group B mutants from which sialic acid residues are removed demonstrate increased binding of both MBL and C4.",
"   </p>",
"   <p>",
"    The importance of MBL for complement activation was illustrated in a study of patients with meningococcal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/38\">",
"     38",
"    </a>",
"    ]. The patients with MBL deficiency had lower levels of activation of various complement components as well as less severe disease, including milder disseminated intravascular coagulation, compared with non-MBL deficient patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology of Neisseria meningitidis infection\", section on 'Other host factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=see_link\">",
"     \"Clinical manifestations of meningococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factor H binding protein (fHBP) on the meningococcal surface binds human factor H, but not factor H of other mammalian species [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/39\">",
"     39",
"    </a>",
"    ]. This property may explain why the meningococcus infects humans exclusively. When fHBP binds to human factor H, it degrades any human C3 deposited on the surface, thus protecting the organism from complement lysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/40\">",
"     40",
"    </a>",
"    ]. Binding of complement factor H enhances survival of N. meningitidis in normal human serum [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. FHBP is sparsely distributed on the surface of N. meningitidis, but immunization with fHBP provides high levels of bactericidal antibodies against the meningococcus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/42\">",
"     42",
"    </a>",
"    ]. Thus, fHBP has generated considerable interest as a vaccine candidate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H454501268#H454501268\">",
"     \"Meningococcal vaccines\", section on 'Group B meningococcus vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Biofilm formation by meningococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The meningococcus forms biofilm-like structures in continuous flow chambers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/43\">",
"     43",
"    </a>",
"    ]. One study suggested that a functional PilE and twitching motility facilitate, but are not absolutely necessary for, biofilm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7688/abstract/43\">",
"     43",
"    </a>",
"    ]. The role of biofilm formation in colonization and disease are not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1762358265\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection with Neisseria meningitidis can produce a variety of clinical manifestations, ranging from transient fever and bacteremia to fulminant disease with death ensuing within hours of the onset of clinical symptoms. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mortality can be very high in patients with meningococcal disease if the infection is not treated appropriately, and long-term sequelae can be severe even in successfully managed cases due primarily to difficulty in managing the endotoxin-induced vascular collapse frequently induced by this organism. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      N. meningitidis is a gram-negative diplococcus approximately 0.7 to 1 micron in diameter. Meningococci can be subdivided into serogroups based upon distinct capsular polysaccharides; eight serogroups most commonly cause infections in humans (A, B, C, X, Y, Z, W135, and L). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      N. meningitidis exclusively infects humans. The pathobiology of meningococcal infection is related to both nasopharyngeal colonization and a variety of virulence factors. Colonization of the nasopharyngeal surface by N. meningitidis is a prerequisite for the development of systemic infection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathobiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      N. meningitidis uses a variety of virulence factors to adhere to and invade human epithelial and endothelial cells and to evade the human immune response. These include phase variation, antigenic variation, and molecular mimicry of human antigens. The principal virulence factors that have been identified to date include pili (also called fimbria), opacity (Opa, Opc) proteins, lipooligosaccharide, and capsular polysaccharide. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Virulence factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Upon contact with epithelial cells, the meningococcus initiates cytoskeletal changes within the cell, such as cortical actin rearrangements. Adhesion mediated by pili, Opc, and OpaA can trigger these rearrangements. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cell entry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      N. meningitidis has important interactions with phagocytic cells and the complement system, which influence pathogenicity and host defense:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Opacity proteins influence the interaction of N. meningitidis strains with polymorphonuclear leukocytes via Opa proteins and with monocytes via Opc.",
"     </li>",
"     <li>",
"      Factor H binding protein (fHBP) on the meningococcal surface binds human factor H, but not factor H of other mammalian species; when it does so, fHBP degrades any human C3 deposited on the surface, thus protecting the organism from complement lysis. Studies suggest that it may be a promising vaccine target.",
"     </li>",
"     <li>",
"      Capsular biosynthesis ceases as the meningococcus enters epithelial cells (such as those in the nasopharynx), an effect that involves reversible inactivation of essential sialic acid biosynthesis genes. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Interaction with phagocytic cells and the complement system'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/1\">",
"      Flexner S. THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS. J Exp Med 1913; 17:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/2\">",
"      Artenstein MS, Gold R, Zimmerly JG, et al. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970; 282:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/3\">",
"      Tettelin H, Saunders NJ, Heidelberg J, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 2000; 287:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/4\">",
"      Sun YH, Bakshi S, Chalmers R, Tang CM. Functional genomics of Neisseria meningitidis pathogenesis. Nat Med 2000; 6:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/5\">",
"      Newcombe J, Cartwright K, Palmer WH, McFadden J. PCR of peripheral blood for diagnosis of meningococcal disease. J Clin Microbiol 1996; 34:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/6\">",
"      Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 2004; 53:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/7\">",
"      Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001; 344:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/8\">",
"      Rudel T, Boxberger HJ, Meyer TF. Pilus biogenesis and epithelial cell adherence of Neisseria gonorrhoeae pilC double knock-out mutants. Mol Microbiol 1995; 17:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/9\">",
"      Virji M, Makepeace K, Peak I, et al. Functional implications of the expression of PilC proteins in meningococci. Mol Microbiol 1995; 16:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/10\">",
"      Rudel T, Scheurerpflug I, Meyer TF. Neisseria PilC protein identified as type-4 pilus tip-located adhesin. Nature 1995; 373:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/11\">",
"      Scheuerpflug I, Rudel T, Ryll R, et al. Roles of PilC and PilE proteins in pilus-mediated adherence of Neisseria gonorrhoeae and Neisseria meningitidis to human erythrocytes and endothelial and epithelial cells. Infect Immun 1999; 67:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/12\">",
"      Power PM, Roddam LF, Rutter K, et al. Genetic characterization of pilin glycosylation and phase variation in Neisseria meningitidis. Mol Microbiol 2003; 49:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/13\">",
"      Warren MJ, Jennings MP. Identification and characterization of pptA: a gene involved in the phase-variable expression of phosphorylcholine on pili of Neisseria meningitidis. Infect Immun 2003; 71:6892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/14\">",
"      K&auml;llstr&ouml;m H, Liszewski MK, Atkinson JP, Jonsson AB. Membrane cofactor protein (MCP or CD46) is a cellular pilus receptor for pathogenic Neisseria. Mol Microbiol 1997; 25:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/15\">",
"      K&auml;llstr&ouml;m H, Islam MS, Berggren PO, Jonsson AB. Cell signaling by the type IV pili of pathogenic Neisseria. J Biol Chem 1998; 273:21777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/16\">",
"      Merz AJ, So M. Attachment of piliated, Opa- and Opc- gonococci and meningococci to epithelial cells elicits cortical actin rearrangements and clustering of tyrosine-phosphorylated proteins. Infect Immun 1997; 65:4341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/17\">",
"      de Vries FP, van Der Ende A, van Putten JP, Dankert J. Invasion of primary nasopharyngeal epithelial cells by Neisseria meningitidis is controlled by phase variation of multiple surface antigens. Infect Immun 1996; 64:2998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/18\">",
"      Callaghan MJ, Jolley KA, Maiden MC. Opacity-associated adhesin repertoire in hyperinvasive Neisseria meningitidis. Infect Immun 2006; 74:5085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/19\">",
"      Virji M, Makepeace K, Ferguson DJ, et al. Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells. Mol Microbiol 1993; 10:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/20\">",
"      de Vries FP, Cole R, Dankert J, et al. Neisseria meningitidis producing the Opc adhesin binds epithelial cell proteoglycan receptors. Mol Microbiol 1998; 27:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/21\">",
"      Kahler CM, Stephens DS. Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin). Crit Rev Microbiol 1998; 24:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/22\">",
"      Mandrell RE, Apicella MA. Lipo-oligosaccharides (LOS) of mucosal pathogens: molecular mimicry and host-modification of LOS. Immunobiology 1993; 187:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/23\">",
"      Mandrell RE, Zollinger WD. Lipopolysaccharide serotyping of Neisseria meningitidis by hemagglutination inhibition. Infect Immun 1977; 16:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/24\">",
"      Kulshin VA, Z&auml;hringer U, Lindner B, et al. Structural characterization of the lipid A component of pathogenic Neisseria meningitidis. J Bacteriol 1992; 174:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/25\">",
"      Cesarini JP, Vandekerkove M, Faucon R, Nicoli J. [Ultrastructure of the wall of Neisseria meningitidis]. Ann Inst Pasteur (Paris) 1967; 113:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/26\">",
"      Kroll JS, Moxon ER. Capsulation and gene copy number at the cap locus of Haemophilus influenzae type b. J Bacteriol 1988; 170:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/27\">",
"      Finne J, Leinonen M, M&auml;kel&auml; PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983; 2:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/28\">",
"      Deghmane AE, Giorgini D, Larribe M, et al. Down-regulation of pili and capsule of Neisseria meningitidis upon contact with epithelial cells is mediated by CrgA regulatory protein. Mol Microbiol 2002; 43:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/29\">",
"      Hammerschmidt S, Hilse R, van Putten JP, et al. Modulation of cell surface sialic acid expression in Neisseria meningitidis via a transposable genetic element. EMBO J 1996; 15:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/30\">",
"      Spinosa MR, Progida C, Tal&agrave; A, et al. The Neisseria meningitidis capsule is important for intracellular survival in human cells. Infect Immun 2007; 75:3594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/31\">",
"      Harrison LH, Shutt KA, Schmink SE, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005. J Infect Dis 2010; 201:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/32\">",
"      Hammerschmidt S, M&uuml;ller A, Sillmann H, et al. Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease. Mol Microbiol 1996; 20:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/33\">",
"      Lin L, Ayala P, Larson J, et al. The Neisseria type 2 IgA1 protease cleaves LAMP1 and promotes survival of bacteria within epithelial cells. Mol Microbiol 1997; 24:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/34\">",
"      McNeil G, Virji M. Phenotypic variants of meningococci and their potential in phagocytic interactions: the influence of opacity proteins, pili, PilC and surface sialic acids. Microb Pathog 1997; 22:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/35\">",
"      Kahler CM, Martin LE, Shih GC, et al. The (alpha2--&gt;8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum. Infect Immun 1998; 66:5939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/36\">",
"      Estabrook MM, Zhou D, Apicella MA. Nonopsonic phagocytosis of group C Neisseria meningitidis by human neutrophils. Infect Immun 1998; 66:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/37\">",
"      Jack DL, Dodds AW, Anwar N, et al. Activation of complement by mannose-binding lectin on isogenic mutants of Neisseria meningitidis serogroup B. J Immunol 1998; 160:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/38\">",
"      Sprong T, Mollnes TE, Neeleman C, et al. Mannose-binding lectin is a critical factor in systemic complement activation during meningococcal septic shock. Clin Infect Dis 2009; 49:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/39\">",
"      Granoff DM, Welsch JA, Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 2009; 77:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/40\">",
"      Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006; 177:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/41\">",
"      Welsch JA, Ram S, Koeberling O, Granoff DM. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 2008; 197:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/42\">",
"      Beernink PT, Leipus A, Granoff DM. Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin Vaccine Immunol 2006; 13:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7688/abstract/43\">",
"      Lappann M, Haagensen JA, Claus H, et al. Meningococcal biofilm formation: structure, development and phenotypes in a standardized continuous flow system. Mol Microbiol 2006; 62:1292.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1276 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.96.59.103-A977B79397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_32_7688=[""].join("\n");
var outline_f7_32_7688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1762358265\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nasopharyngeal carriage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Virulence factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pili (fimbria)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Opacity proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Lipooligosaccharide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Capsular polysaccharides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cell entry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Survival within epithelial cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Interaction with phagocytic cells and the complement system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Biofilm formation by meningococcus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1762358265\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=related_link\">",
"      Clinical manifestations of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27285?source=related_link\">",
"      Diagnosis of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=related_link\">",
"      Epidemiology of Neisseria meningitidis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=related_link\">",
"      Epidemiology of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=related_link\">",
"      Treatment and prevention of meningococcal infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_32_7689="Classification and evaluation of myoclonus";
var content_f7_32_7689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification and evaluation of myoclonus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/32/7689/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/32/7689/contributors\">",
"     John N Caviness, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/32/7689/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/32/7689/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/32/7689/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/32/7689/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/32/7689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus is a clinical sign that is characterized by brief, shock-like, involuntary movements caused by muscular contractions or inhibitions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/1\">",
"     1",
"    </a>",
"    ]. Muscular contractions produce positive myoclonus, whereas muscular inhibitions produce negative myoclonus (ie, asterixis). Patients will usually describe myoclonus as consisting of \"jerks,\" \"shakes,\" or \"spasms.\"",
"   </p>",
"   <p>",
"    Myoclonic movements have many possible etiologies, anatomic sources, and pathophysiologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/2\">",
"     2",
"    </a>",
"    ]. Myoclonus may be classified by clinical presentation, examination findings, clinical neurophysiology testing, and etiology.",
"   </p>",
"   <p>",
"    This topic will review the classification and evaluation of myoclonus. Treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6537?source=see_link\">",
"     \"Treatment of myoclonus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMIC AND PHYSIOLOGIC CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the clinical and etiologic classification discussed below, myoclonus can be classified by the localization of the physiologic mechanism that generates it (",
"    <a class=\"graphic graphic_table graphicRef62397 \" href=\"UTD.htm?27/18/27948\">",
"     table 1",
"    </a>",
"    ). These anatomic-physiologic categories are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cortical",
"     </li>",
"     <li>",
"      Cortical-subcortical",
"     </li>",
"     <li>",
"      Subcortical-nonsegmental",
"     </li>",
"     <li>",
"      Segmental",
"     </li>",
"     <li>",
"      Peripheral",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This classification paradigm can help with localization of the underlying lesion, aid in the diagnosis of certain disorders that have a characteristic myoclonus physiology, and guide treatment options that may be useful for some physiologic types of myoclonus but not others [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cortical",
"    </span>",
"    &nbsp;&mdash;&nbsp;With cortical myoclonus, a focal discharge from the primary sensorimotor cortex causes a myoclonic jerk after a time interval required for corticospinal transmission. This type of myoclonus occurs because of insufficient inhibition within neuronal circuits of the primary motor cortex, primary sensory cortex, or both.",
"   </p>",
"   <p>",
"    The detailed body mapping found in the sensorimotor cortex explains the common occurrence of multifocal myoclonus when there is bilateral diffuse dysfunction of the sensorimotor cortex. It likewise explains the occurrence of focal myoclonus when the lesion has a focal distribution. Bisynchronous or generalized myoclonus may occur when the focal discharge spreads through cortico-cortico and transcallosal pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/4\">",
"     4",
"    </a>",
"    ]. Rapid generalization of cortical myoclonus can produce myoclonic seizures in certain epileptic syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cortical myoclonus may occur with reflex sensory stimulation (cortical reflex myoclonus), with muscle activation (cortical action myoclonus), from rest (eg, focal motor seizure), or any combination of the above.",
"   </p>",
"   <p>",
"    In cortical reflex myoclonus, an exaggerated cortical response to somatosensory stimuli produces the jerk, but subsequently the whole sensorimotor cortex generates giant somatosensory evoked cortical potentials (SEP) and reflex myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/6\">",
"     6",
"    </a>",
"    ]. Rhythmic or semirhythmic discharges from the sensorimotor cortex can produce a repetitive movement that resembles tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A unifying pathogenic mechanism for cortical myoclonus remains elusive, and there may be mechanism heterogeneity. The relative contribution of intracortical pathology versus abnormal activity projecting into the sensorimotor cortex is not known. Numerous abnormalities have been suspected to be important, including pathways involving GABAergic, serotoninergic, and other neurotransmitters, and cerebellar systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cortical-subcortical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cortical-subcortical physiology is the major mechanism for myoclonic seizures that occur in primary generalized epileptic syndromes (eg, juvenile myoclonic epilepsy) and in some other instances (eg, minipolymyoclonus).",
"   </p>",
"   <p>",
"    Examples include juvenile myoclonic epilepsy and absence epilepsy, where thalamic networks are believed to abnormally couple with widespread cortical areas to produce excessive neuronal activity and myoclonic seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. The resulting myoclonic jerks are commonly generalized or bisynchronous.",
"   </p>",
"   <p>",
"    The physiology of cortical-subcortical myoclonus involves abnormal, paroxysmal, and excessive oscillation in bidirectional connections between cortical and subcortical sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Subcortical-nonsegmental",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcortical-nonsegmental myoclonus is generated from a site that is subcortical, but the crucial feature is that the myoclonus manifests far beyond the segments that are near the originating site.",
"   </p>",
"   <p>",
"    The best characterized types of subcortical-nonsegmental physiologies are reticular-reflex myoclonus and propriospinal myoclonus. In both of these examples, the abnormal activity begins in a focal area of the neuraxis and then spreads in both rostral and caudal directions, producing generalized myoclonus due to the bilateral pathways involved.",
"   </p>",
"   <p>",
"    There is also evidence of a subcortical-nonsegmental physiology for the myoclonus-dystonia syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/9\">",
"     9",
"    </a>",
"    ]. The exact subcortical generating site of myoclonus-dystonia is unknown, but the myoclonus distribution extends across the head, neck, upper torso, and bilateral arm segments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Segmental",
"    </span>",
"    &nbsp;&mdash;&nbsp;Segmental myoclonus is generated at a particular segment or contiguous segments of the brainstem",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spinal cord. The pathologic motor oscillations in this type of myoclonus occur at a lower frequency than what is usually seen in tremor.",
"   </p>",
"   <p>",
"    Segmental myoclonus manifests at, or close to, that particular segment or contiguous segments of the body (eg, palatal myoclonus, spinal segmental myoclonus).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Peripheral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral myoclonus arises as a consequence of a peripheral nervous system lesion producing hyperactive motor discharges to its muscle (eg, hemifacial spasm). The possible role of central reorganization is not well defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL AND ETIOLOGIC CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification scheme of Marsden and colleagues organizes the numerous etiologies of myoclonus into four major categories [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Physiologic",
"     </li>",
"     <li>",
"      Essential",
"     </li>",
"     <li>",
"      Epileptic",
"     </li>",
"     <li>",
"      Secondary (symptomatic)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each clinical category contains myoclonus arising from various etiologies and pathophysiologic mechanisms. Thus, differentiation by clinical-etiologic category is not always pure. In addition, a single etiology can produce different types of myoclonus, and occasional patients may demonstrate more than one type of myoclonus.",
"   </p>",
"   <p>",
"    The classification scheme shown in the table (",
"    <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"     table 2",
"    </a>",
"    ) has been modified from the original [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/1\">",
"     1",
"    </a>",
"    ] to account for subsequent discoveries and etiologies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Olmsted County, Minnesota, the average annual incidence rate for myoclonus was 1.3 cases per 100,000 person-years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/10\">",
"     10",
"    </a>",
"    ]. The lifetime prevalence of myoclonus in 1990 was 8.6 per 100,000 population. Secondary (symptomatic) myoclonus (72 percent) was the most common clinical category, followed by epileptic myoclonus (17 percent) and essential myoclonus (11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Post-hypoxic state, neurodegenerative disease, and epilepsy syndromes are the most common causes of myoclonus. Toxic-metabolic and drug-induced cases are particularly common in the hospital setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Physiologic myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic myoclonus is a normal phenomenon that occurs in healthy people [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/1\">",
"     1",
"    </a>",
"    ]. There is minimal or no associated disability and the physical examination is typically without abnormality.",
"   </p>",
"   <p>",
"    The most familiar examples of physiologic myoclonus are jerks during sleep or sleep transitions (",
"    <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Jerks associated with sleep",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varieties of sudden movement that occur during sleep or sleep transitions are partial myoclonic jerks, massive myoclonic jerks (hypnic jerks), and periodic movements of sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Partial myoclonic jerks are usually multifocal and occur in distal muscles",
"     </li>",
"     <li>",
"      Massive myoclonic jerks are generalized and affect trunk and proximal muscles",
"     </li>",
"     <li>",
"      Periodic movements of sleep (nocturnal myoclonus) consist of stereotyped repetitive dorsiflexion of the toes and feet, sometimes with flexion of the knees and hips [",
"      <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/12\">",
"       12",
"      </a>",
"      ]. The same types of movements occur in the restless legs syndrome and can disrupt sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/13\">",
"       13",
"      </a>",
"      ]. Some authors maintain that nocturnal myoclonus is too slow and prolonged to be classified as myoclonus, and that periodic movements of sleep is the preferred term [",
"      <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link&amp;anchor=H16#H16\">",
"       \"Restless legs syndrome\", section on 'Periodic limb movements of sleep'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since these types of myoclonus occur around or during sleep, a bed partner is often more aware of the myoclonus than the affected individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Essential myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In essential myoclonus, the myoclonus is the most prominent or only clinical finding (ie, an \"essential\" phenomenon). The patient usually experiences some mild disability. Progression is slow or absent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/1\">",
"     1",
"    </a>",
"    ]. Cognition is normal.",
"   </p>",
"   <p>",
"    Essential myoclonus is divided into sporadic and hereditary and forms (",
"    <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Sporadic (or idiopathic) essential myoclonus is a heterogeneous entity regarding distribution, exacerbating factors, and findings on neurologic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/14\">",
"     14",
"    </a>",
"    ]. Some cases probably have false-negative family histories and actually represent hereditary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Palatal myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palatal myoclonus is most often secondary to a brainstem",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cerebellar lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=see_link&amp;anchor=H24#H24\">",
"     \"Symptomatic (secondary) myoclonus\", section on 'Palatal myoclonus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some patients have no apparent structural lesion and are considered to have essential palatal myoclonus. In such cases, the myoclonus is usually characterized by contractions of the tensor veli palatini. In contrast, secondary (symptomatic) palatal myoclonus is usually characterized by contractions of the levator veli palatini. Middle ear myoclonus can be either essential or secondary and is characterized by contractions of the tensor tympani",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stapedius muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/15-22\">",
"     15-22",
"    </a>",
"    ]. These conditions may cause tinnitus or ear clicking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hereditary essential myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary essential myoclonus has the following clinical characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onset typically before age 20 years",
"     </li>",
"     <li>",
"      Autosomal dominant inheritance with variable expressivity",
"     </li>",
"     <li>",
"      A benign course compatible with an active life and normal lifespan",
"     </li>",
"     <li>",
"      Absence of cerebellar ataxia, spasticity, dementia, and seizures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The myoclonus usually occurs throughout the arms and axial muscles. It is exacerbated by muscle activation and is markedly diminished with alcohol ingestion. Hereditary essential myoclonus demonstrates a subcortical-nonsegmental physiology [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Myoclonus-dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dystonia is a common feature of hereditary essential myoclonus, and when present, the condition is termed myoclonus-dystonia syndrome. In addition to myoclonus, this syndrome is characterized by dystonia of variable, but typically mild, severity that often presents as cervical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    limb dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/24\">",
"     24",
"    </a>",
"    ]. The mean age of symptom onset is six years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/25\">",
"     25",
"    </a>",
"    ], occurring earlier in girls than in boys (median five versus eight years) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/26\">",
"     26",
"    </a>",
"    ]. Although unusual after age 20, onset as late as 75 years has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective report of 41 patients with myoclonus-dystonia syndrome and mutations of the epsilon-sarcoglycan gene (SGCE or DYT11) on chromosome 7q21, the myoclonus was predominantly localized to the neck and trunk or proximal upper limbs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/25\">",
"     25",
"    </a>",
"    ]. The myoclonic movements consisted of short jerks (mean duration 95 ms, range 25 to 256 ms) occurring at rest, during action, and during posture. Myoclonus was either isolated or associated with mild to moderate dystonia. Twenty-two percent of patients had spontaneous improvement in dystonia lasting one to 20 years.",
"   </p>",
"   <p>",
"    In most cases, myoclonus-dystonia confers little or no functional disability and is compatible with a normal lifespan [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/24,28\">",
"     24,28",
"    </a>",
"    ]. However, the course is unpredictable, and a minority of patients develops progressive symptoms that can lead to severe motor disability [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/24,28,29\">",
"     24,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myoclonus-dystonia is genetically heterogeneous. Mutations involving the SGCE gene are the most frequent identified cause but are found in less than one-half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. Less commonly, myoclonus-dystonia is associated with mutations involving the DYT15 locus on chromosome 18p11 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/35\">",
"     35",
"    </a>",
"    ]. In a single family, a phenotype of levodopa-responsive myoclonus with dystonia was linked to mutations in the tyrosine hydroxylase gene [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/36\">",
"     36",
"    </a>",
"    ]. Additional genes are likely to be associated with this syndrome.",
"   </p>",
"   <p>",
"    Some SGCE mutation carriers have psychiatric disturbances, mainly obsessive-compulsive disorder and alcohol dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to other types of sarcoglycan, which are expressed mainly in muscle and are associated with muscular dystrophy, epsilon-sarcoglycan is expressed in the brain and other non-muscle tissues, but its normal function is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/30\">",
"     30",
"    </a>",
"    ]. Most SGCE mutations are \"loss of function,\" and maternal imprinting has been associated with reduced penetrance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/40\">",
"     40",
"    </a>",
"    ]. Exactly how the loss of SGCE function results in myoclonus or dystonia is not known, but epsilon-sarcoglycan has been localized to areas important for movement, such as the cerebellum and monoamine brainstem nuclei, including dopaminergic neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Epileptic myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epileptic myoclonus refers to the presence of myoclonus in the setting of epilepsy (",
"    <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"     table 2",
"    </a>",
"    ). Seizures dominate the clinical picture in epileptic myoclonus. The etiology may be idiopathic, genetic, or a static encephalopathy.",
"   </p>",
"   <p>",
"    Myoclonus can occur as either one of several components of a seizure, the only seizure manifestation (myoclonic seizure), or as one of multiple seizure types within an epileptic syndrome. Different types of epileptic myoclonus may demonstrate a cortical or cortical-subcortical physiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Fragments of epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fragments of epilepsy include the following examples (",
"    <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Isolated epileptic myoclonic jerks",
"     </li>",
"     <li>",
"      Epilepsia partialis continua (focal status epilepticus)",
"     </li>",
"     <li>",
"      Idiopathic stimulus-sensitive myoclonus",
"     </li>",
"     <li>",
"      Photosensitive myoclonus",
"     </li>",
"     <li>",
"      Absences with a minor myoclonic component",
"     </li>",
"     <li>",
"      Epilepsy with myoclonic absences",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In epilepsia partialis continua, the myoclonus is spontaneous and focal; it occurs irregularly or regularly at intervals no longer than 10 seconds, is confined to one part of the body, and continues for a period of hours, days, or weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Myoclonic epilepsy syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus is associated with a number of epilepsy syndromes that mostly present in infancy or childhood (",
"    <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infantile spasms (West syndrome)",
"     </li>",
"     <li>",
"      Severe myoclonic epilepsy of infancy (Dravet syndrome)",
"     </li>",
"     <li>",
"      Benign myoclonic epilepsy of infancy",
"     </li>",
"     <li>",
"      Lennox-Gastaut syndrome",
"     </li>",
"     <li>",
"      Myoclonic astatic epilepsy (Doose syndrome)",
"     </li>",
"     <li>",
"      Cryptogenic myoclonus epilepsy (Aicardi)",
"     </li>",
"     <li>",
"      Juvenile myoclonic epilepsy (Janz syndrome)",
"     </li>",
"     <li>",
"      Familial cortical myoclonic tremor with epilepsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In myoclonic seizures, the characteristic seizure movement manifestation is myoclonus. They may be confused with other seizures that result in jerks (eg, atonic and tonic seizures). In myoclonic epilepsy syndromes, myoclonic seizures are usually accompanied by other seizure types, such as generalized tonic-clonic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    absence in patients with juvenile myoclonic epilepsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15849?source=see_link&amp;anchor=H88577538#H88577538\">",
"     \"Juvenile myoclonic epilepsy\", section on 'Clinical Features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    True myoclonic seizures result in brief positive myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/5\">",
"     5",
"    </a>",
"    ]. On electroencephalography (EEG), the myoclonus is accompanied by a generalized (primary or secondary) ictal epileptiform discharge, but the myoclonus itself may be generalized, segmental, or focal.",
"   </p>",
"   <p>",
"    Myoclonic seizures occurring in a primary generalized epileptic syndrome exhibit a cortical-subcortical physiology, while those occurring in a secondary generalized epileptic syndrome exhibit a cortical physiology with a tendency to spread.",
"   </p>",
"   <p>",
"    The genetics of the myoclonic epilepsies is heterogeneous, but in many instances, mutations have been found in ion channels or neurotransmitter receptor genes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Familial cortical myoclonic tremor with epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term familial cortical myoclonic tremor with epilepsy encompasses a large number of syndrome labels (",
"    <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"     table 2",
"    </a>",
"    ) used to describe a genetically heterogeneous phenotype with the following core clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Autosomal dominant inheritance",
"     </li>",
"     <li>",
"      Adult onset",
"     </li>",
"     <li>",
"      Distal action tremor and myoclonus",
"     </li>",
"     <li>",
"      Infrequent, secondarily generalized tonic-clonic seizures",
"     </li>",
"     <li>",
"      Relatively benign course, typically with normal cognition",
"     </li>",
"     <li>",
"      Responsiveness to anticonvulsants",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasional patients with this syndrome may exhibit frequent seizures, other seizure types, larger arrhythmic myoclonic jerks, or abnormal cognition.",
"   </p>",
"   <p>",
"    Clinical neurophysiology testing reveals distal rhythmic small amplitude myoclonus (tremor) with action (voluntary movement) produced by electromyographic discharges exhibiting a cortical physiology. Additional typical features are enlarged (giant) somatosensory evoked potentials and enhanced long latency EMG reflexes at rest, consistent with cortical reflex myoclonus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34491582\">",
"    <span class=\"h2\">",
"     Primary myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated myoclonus is seen in primary progressive myoclonus of aging and familial cortical myoclonus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34491589\">",
"    <span class=\"h3\">",
"     Primary progressive myoclonus of aging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older individuals may develop a progressive isolated myoclonus without any cause or other syndrome being identified, a condition termed primary progressive myoclonus of aging [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/48\">",
"     48",
"    </a>",
"    ]. There is a progressive development of",
"    <span class=\"nowrap\">",
"     focal/asymmetric",
"    </span>",
"    predominantly action myoclonus. The progression of the myoclonus may plateau once it is severe. The physiology is uniformly cortical with variable reflex features. These cases do respond to a cortical physiology treatment approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6537?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of myoclonus\", section on 'Cortical myoclonus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association with older individuals suggests that primary progressive myoclonus of aging is a neurodegenerative syndrome but the etiology awaits clarification. The cause of this syndrome is probably heterogeneous and no autopsies have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34491596\">",
"    <span class=\"h3\">",
"     Familial cortical myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial cortical myoclonus, described in one large Mennonite family from Canada, is an autosomal dominant condition with onset from the second to seventh decade of life, and has been tentatively linked to a mutation in the NOL3 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/49\">",
"     49",
"    </a>",
"    ]. The phenotype is characterized by a slowly progressive, stimulus-evoked, multifocal cortical myoclonus involving the face and limbs that becomes disabling late in the course. Neither seizures nor dystonia have been observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Symptomatic (secondary) myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus that occurs as a secondary symptom of a neurologic or non-neurologic disorder has been traditionally termed symptomatic. This category is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=see_link\">",
"     \"Symptomatic (secondary) myoclonus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptomatic myoclonus can occur in association with conditions that span the entire spectrum of neurologic disease (",
"    <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"     table 2",
"    </a>",
"    ). Often there is clinical or pathologic evidence of diffuse nervous system involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the evaluation of a patient with myoclonus may be conceptualized into four parts:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Syndrome identification based upon clinical features",
"     </li>",
"     <li>",
"      Ancillary laboratory testing",
"     </li>",
"     <li>",
"      Clinical neurophysiology",
"     </li>",
"     <li>",
"      Testing for rare causes of myoclonus",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Syndrome identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial steps in the evaluation of a patient with myoclonus are the history and examination (",
"    <a class=\"graphic graphic_table graphicRef51320 \" href=\"UTD.htm?26/40/27277\">",
"     table 3",
"    </a>",
"    ). The findings should identify which major clinical and etiologic classification (physiologic, essential, epileptic, or secondary myoclonus) best reflects the circumstances of the patient (",
"    <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most myoclonic movements are easily diagnosed by clinical observation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/50\">",
"     50",
"    </a>",
"    ]. The examination of a patient with myoclonus should delineate the distribution, temporal profile, and activation characteristics of the myoclonic movement.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The distribution can be focal, multifocal, segmental, or generalized. A multifocal distribution may have bilaterally synchronous movements as well.",
"     </li>",
"     <li>",
"      The temporal profile can be continuous or intermittent, as well as rhythmic or irregular. Intermittent myoclonus can occur as isolated or repetitive trains of jerks.",
"     </li>",
"     <li>",
"      The activation of the myoclonus may be at rest (spontaneous), induced by various stimuli (reflex myoclonus), induced by voluntary movement (action myoclonus), or by some combination of these. All the possible activation characteristics should be noted as absent or present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasionally, it may be difficult to differentiate myoclonus from other involuntary movements (eg, chorea, dystonia, tremor) by observation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/50\">",
"     50",
"    </a>",
"    ]. In this situation, clinical neurophysiology studies can be particularly helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Clinical neurophysiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Myoclonus induced by drugs or toxins is potentially treatable, since the myoclonus typically resolves upon withdrawal of the offending agent(s). It is important to scrutinize all drugs, either in isolation or combination, when evaluating for a potential causative role in myoclonus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ancillary testing should be performed if the myoclonus etiology is unclear from the history and examination findings. Suggested studies are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Electrolytes (including bismuth, calcium, magnesium)",
"     </li>",
"     <li>",
"      Glucose",
"     </li>",
"     <li>",
"      Renal function tests",
"     </li>",
"     <li>",
"      Liver function tests",
"     </li>",
"     <li>",
"      Thyroid antibodies and thyroid function tests",
"     </li>",
"     <li>",
"      Drug and toxin screen, if warranted by clinical suspicion",
"     </li>",
"     <li>",
"      Paraneoplastic antibodies",
"     </li>",
"     <li>",
"      Electroencephalography (EEG)",
"     </li>",
"     <li>",
"      Brain imaging",
"     </li>",
"     <li>",
"      Spine imaging (if focal or segmental)",
"     </li>",
"     <li>",
"      Cerebrospinal fluid analysis in select cases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such testing covers the most common disturbances of electrolyte balance and acquired metabolic disorders. Imaging of the brain and spinal cord may reveal lesions or atrophy supporting a specific myoclonus etiology. Cerebrospinal fluid analysis is useful to differentiate an",
"    <span class=\"nowrap\">",
"     infectious/inflammatory",
"    </span>",
"    etiology from a toxic, drug-induced, or metabolic etiology.",
"   </p>",
"   <p>",
"    Electroencephalography (EEG) can identify both ictal and interictal patterns in the epileptic myoclonus category. As examples, generalized spikes and a 3 to 6 Hz spike-and-wave pattern are typical for primary generalized myoclonic epilepsy, whereas a 3 Hz spike-and-wave is seen in absence epilepsy syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Clinical neurophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical neurophysiology testing is useful to determine the physiologic classification of myoclonus and support or confirm the neuroanatomic localization and etiology (",
"    <a class=\"graphic graphic_table graphicRef56405 \" href=\"UTD.htm?23/18/23852\">",
"     table 4",
"    </a>",
"    ). In addition, it is helpful when clinical observation alone is unable to distinguish myoclonus from other involuntary movements such as chorea, dystonia, and tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When using multiple techniques for physiologic classification of myoclonus, the results from the EEG obtained in basic ancillary testing (discussed above) are combined with the following methods [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/3,50\">",
"     3,50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Surface electromyography (EMG)",
"     </li>",
"     <li>",
"      Simultaneous electroencephalography-electromyography polygraphy (EEG-EMG polygraphy)",
"     </li>",
"     <li>",
"      Somatosensory evoked potentials (SEPs)",
"     </li>",
"     <li>",
"      Jerk-locked back-averaging of EEG transients",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      SEPs to EMG discharges",
"     </li>",
"     <li>",
"      Long latency EMG responses to peripheral nerve stimulation (eg, C reflex)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surface EMG recording can demonstrate the abrupt and brief muscle contraction that is characteristic of positive myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, EMG can reveal the silent period of negative myoclonus (asterixis).",
"   </p>",
"   <p>",
"    EEG-EMG polygraphy is the most important clinical neurophysiology study, since it can show the approximate relationship of EEG activity with myoclonus, and determine which muscles are most frequently involved with the myoclonic jerks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/50\">",
"     50",
"    </a>",
"    ]. As an example, jerk-locked back-averaging of EEG waveforms to EMG discharges can detect small EEG potentials that are temporally related to myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest clinical neurophysiology testing if a diagnosis is not forthcoming after the history, examination, and ancillary testing are performed. The treatment implications of physiologic classification are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6537?source=see_link\">",
"     \"Treatment of myoclonus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Major categories of the physiologic classification used here primarily refer to the neuroanatomic source of the myoclonus. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Anatomic and physiologic classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Findings associated with major anatomic-physiologic categories",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic clinical neurophysiology findings for each major anatomic-physiologic category of myoclonus are discussed here briefly and are summarized in the tables (",
"    <a class=\"graphic graphic_table graphicRef56405 \" href=\"UTD.htm?23/18/23852\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51170 \" href=\"UTD.htm?33/33/34333\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7689/abstract/3,50\">",
"     3,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cortical &mdash; Cortical myoclonus originates as a focal discharge from the primary sensorimotor cortex. The EMG discharge duration is typically &lt;75 ms, and a focal back-averaged EEG transient is present. Enlarged (giant) SEPs and enhanced long latency EMG responses (eg, the C reflex) are characteristic of cortical reflex myoclonus physiology.",
"     </li>",
"     <li>",
"      Cortical-subcortical &mdash; The physiology of cortical-subcortical myoclonus involves abnormal, paroxysmal, and excessive oscillation in bidirectional connections between cortical and subcortical sites. On surface EMG, discharge duration is typically &lt;100 ms, and the associated EEG transient (eg, spike-and-wave) is usually diffuse. With back-averaging, time-locked correlation of EEG transients to EMG discharges is typical. Giant SEPs and enhanced long-latency reflexes are sometimes seen.",
"     </li>",
"     <li>",
"      Subcortical-nonsegmental &mdash; Subcortical-nonsegmental myoclonus is generated from subcortical but not segmental sources (eg, myoclonus-dystonia syndrome). Variable EMG discharge duration is characteristic. Jerk-locked back averaging shows no correlation of EEG transients to EMG discharges. SEPs are normal. Some cases have an EMG reflex response to sound stimulation.",
"     </li>",
"     <li>",
"      Segmental &mdash; Segmental myoclonus is generated at a particular segment or contiguous segments of the brainstem",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      spinal cord. EMG discharge duration is typically &gt;100 ms. There are usually rhythmic EMG discharges. With EMG reflex testing, some types of segmental myoclonus may show a very short latency response that is incompatible with a supraspinal origin.",
"     </li>",
"     <li>",
"      Peripheral &mdash; Peripheral myoclonus is driven from a peripheral site (ie, a peripheral nerve). Variable EMG discharge duration and irregularity is characteristic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Testing for rare causes of myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional testing for conditions that rarely cause myoclonus can be considered when the standard evaluation, including clinical neurophysiology studies, fails to reveal a cause. Some examples include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Body imaging for occult cancer, even in the absence of paraneoplastic antibodies",
"     </li>",
"     <li>",
"      Evaluation for malabsorption disorders such as Celiac sprue and Whipple disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"       \"Diagnosis of celiac disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11833?source=see_link&amp;anchor=H9#H9\">",
"       \"Whipple's disease\", section on 'Differential diagnosis and evaluation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Enzyme assays for neuraminidase deficiency (Sialidosis) and biotinidase deficiency (Multiple carboxylase deficiency)",
"     </li>",
"     <li>",
"      Evaluation for Wilson's disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link\">",
"       \"Tests used in the diagnosis of Wilson disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Evaluation for ataxia-telangiectasia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link&amp;anchor=H13#H13\">",
"       \"Ataxia-telangiectasia\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Genetic testing (and tissue biopsy if indicated) for inherited disorders, such as Unverricht-Lundborg disease (EPM1 gene), Lafora body disease (EPM2A and EPM2B genes), neuronal ceroid lipofuscinosis, and Huntington disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29832?source=see_link\">",
"       \"Huntington disease: Clinical features and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Evaluation for mitochondrial disorders, including serum lactate, muscle biopsy, and genetic testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice and order of such testing is guided by the clinical circumstances and suspicion for a specific diagnosis or group of etiologies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2754?source=see_link\">",
"       \"Patient information: Myoclonus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus is characterized by brief, shock-like, involuntary movements caused by muscular contractions or inhibitions. Muscular contractions produce positive myoclonus, whereas muscular inhibitions produce negative myoclonus (asterixis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical and etiologic classification scheme uses four major categories to organize myoclonus (",
"      <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"       table 2",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical and etiologic classification'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Physiologic",
"     </li>",
"     <li>",
"      Essential",
"     </li>",
"     <li>",
"      Epileptic",
"     </li>",
"     <li>",
"      Symptomatic (secondary)",
"      <br/>",
"      <br/>",
"      Of these, secondary myoclonus is the most common type.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physiologic myoclonus is a normal phenomenon that can occur in healthy people. There is minimal or no associated disability and the physical examination is typically without abnormality. The most familiar examples of physiologic myoclonus are jerks during sleep or sleep transitions (",
"      <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Physiologic myoclonus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In essential myoclonus, the myoclonus is the most prominent or only clinical finding. Hereditary and sporadic forms exist (",
"      <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Essential myoclonus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epileptic myoclonus refers to the presence of myoclonus in the setting of epilepsy (",
"      <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"       table 2",
"      </a>",
"      ). Seizures dominate the clinical picture in epileptic myoclonus. The etiology may be idiopathic, genetic, or a static encephalopathy. Subcategories of epileptic myoclonus include the following (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Epileptic myoclonus'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fragments of epilepsy",
"     </li>",
"     <li>",
"      Myoclonic epilepsy syndromes",
"     </li>",
"     <li>",
"      Familial cortical myoclonic tremor with epilepsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolated myoclonus is seen in primary progressive myoclonus of aging and familial cortical myoclonus. (See",
"      <a class=\"local\" href=\"#H34491589\">",
"       'Primary progressive myoclonus of aging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34491596\">",
"       'Familial cortical myoclonus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic myoclonus occurs as a secondary symptom of a neurologic or non-neurologic disorder. Symptomatic myoclonus can occur in association with conditions that span the entire spectrum of neurologic disease (",
"      <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Symptomatic (secondary) myoclonus'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Symptomatic myoclonus is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=see_link\">",
"       \"Symptomatic (secondary) myoclonus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The anatomic and physiologic classification scheme categorizes myoclonus according to the localization of the mechanism that generates it (",
"      <a class=\"graphic graphic_table graphicRef62397 \" href=\"UTD.htm?27/18/27948\">",
"       table 1",
"      </a>",
"      ). The categories are as follows (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomic and physiologic classification'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cortical",
"     </li>",
"     <li>",
"      Cortical-subcortical",
"     </li>",
"     <li>",
"      Subcortical-nonsegmental",
"     </li>",
"     <li>",
"      Segmental",
"     </li>",
"     <li>",
"      Peripheral",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guidelines for the evaluation of a patient with myoclonus may be conceptualized into four parts (",
"      <a class=\"graphic graphic_table graphicRef51320 \" href=\"UTD.htm?26/40/27277\">",
"       table 3",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Evaluation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Syndrome identification",
"     </li>",
"     <li>",
"      Ancillary laboratory testing",
"     </li>",
"     <li>",
"      Clinical neurophysiology",
"     </li>",
"     <li>",
"      Testing for rare causes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most myoclonic movements are easily diagnosed by clinical observation. The examination of a patient with myoclonus should delineate the distribution, temporal profile, and activation characteristics of the myoclonus (",
"      <a class=\"graphic graphic_table graphicRef51170 \" href=\"UTD.htm?33/33/34333\">",
"       table 5",
"      </a>",
"      ). Ancillary testing should be performed if the etiology remains unclear. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Syndrome identification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Ancillary studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical neurophysiology testing is useful to determine the physiologic classification of myoclonus (",
"      <a class=\"graphic graphic_table graphicRef56405 \" href=\"UTD.htm?23/18/23852\">",
"       table 4",
"      </a>",
"      ). In addition, it is helpful when clinical observation alone is unable to distinguish myoclonus from other involuntary movements such as chorea, dystonia, and tremor. Simultaneous electroencephalography-electromyography polygraphy is the most important clinical neurophysiology study, since it can show the approximate relationship of electroencephalography activity with myoclonus, and determine which muscles are most frequently involved with the myoclonic jerks. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Clinical neurophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest clinical neurophysiology testing if a diagnosis is not forthcoming after history, examination and ancillary testing. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Clinical neurophysiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Marsden CD, Hallett M, Fahn S. The nosology and pathophysiology of myoclonus. In: Movement Disorders, Marsden CD, Fahn S (Eds), Butterworths, London 1982. p.196.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/2\">",
"      Caviness JN, Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol 2004; 3:598.",
"     </a>",
"    </li>",
"    <li>",
"     Caviness, JN. Clinical Neurophysiology of Myoclonus. In: Handbook of Clinical Neurophysiology, Vol 1: Movement Disorders, M, Hallett (Ed), Elsevier, Amsterdam 2003. p.521.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/4\">",
"      Brown P, Day BL, Rothwell JC, et al. Intrahemispheric and interhemispheric spread of cerebral cortical myoclonic activity and its relevance to epilepsy. Brain 1991; 114 ( Pt 5):2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/5\">",
"      Guerrini R, Bonanni P, Parmeggiani L, et al. Pathophysiology of myoclonic epilepsies. Adv Neurol 2005; 95:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/6\">",
"      Hitomi T, Ikeda A, Matsumoto R, et al. Generators and temporal succession of giant somatosensory evoked potentials in cortical reflex myoclonus: epicortical recording from sensorimotor cortex. Clin Neurophysiol 2006; 117:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/7\">",
"      Ikeda A, Kakigi R, Funai N, et al. Cortical tremor: a variant of cortical reflex myoclonus. Neurology 1990; 40:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/8\">",
"      Snead OC 3rd. Basic mechanisms of generalized absence seizures. Ann Neurol 1995; 37:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/9\">",
"      Nitschke MF, Erdmann C, Trillenberg P, et al. Functional MRI reveals activation of a subcortical network in a 5-year-old girl with genetically confirmed myoclonus-dystonia. Neuropediatrics 2006; 37:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/10\">",
"      Caviness JN, Alving LI, Maraganore DM, et al. The incidence and prevalence of myoclonus in Olmsted County, Minnesota. Mayo Clin Proc 1999; 74:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/11\">",
"      Lugaresi E, Cirignotta F, Coccagna G, Montagna P. Nocturnal myoclonus and restless legs syndrome. Adv Neurol 1986; 43:295.",
"     </a>",
"    </li>",
"    <li>",
"     Marsden, CD, Fahn, S. Problems in the dyskinesias. In: Movement Disorders, Vol 2, Marsden, CE, Fahn, S, (Eds), Butterworths, London 1987. p.305.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/13\">",
"      Krueger BR. Restless legs syndrome and periodic movements of sleep. Mayo Clin Proc 1990; 65:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/14\">",
"      Bressman S, Fahn S. Essential myoclonus. Adv Neurol 1986; 43:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/15\">",
"      Wakata N, Sugimoto H, Iguchi H, et al. A case of voluntary palatal myoclonus with ear click: relationship between palatal myoclonus and click. Eur Neurol 2002; 48:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/16\">",
"      Fabiani G, Teive HA, S&aacute; D, et al. Palatal myoclonus: report of two cases. Arq Neuropsiquiatr 2000; 58:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/17\">",
"      Kutukcu Y, Imirzalioglu N, Odabasi Z, et al. Essential palatal myoclonus in monozygotic male twins. J Neurol 2003; 250:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/18\">",
"      Bento RF, Sanchez TG, Miniti A, Tedesco-Marchesi AJ. Continuous, high-frequency objective tinnitus caused by middle ear myoclonus. Ear Nose Throat J 1998; 77:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/19\">",
"      Golz A, Fradis M, Netzer A, et al. Bilateral tinnitus due to middle-ear myoclonus. Int Tinnitus J 2003; 9:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/20\">",
"      Golz A, Fradis M, Martzu D, et al. Stapedius muscle myoclonus. Ann Otol Rhinol Laryngol 2003; 112:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/21\">",
"      Oliveira CA, Negreiros J&uacute;nior J, Cavalcante IC, et al. Palatal and middle-ear myoclonus: a cause for objective tinnitus. Int Tinnitus J 2003; 9:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/22\">",
"      Bhimrao SK, Masterson L, Baguley D. Systematic review of management strategies for middle ear myoclonus. Otolaryngol Head Neck Surg 2012; 146:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/23\">",
"      Mahloudji M, Pikielny RT. Hereditary essential myoclonus. Brain 1967; 90:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/24\">",
"      Kinugawa K, Vidailhet M, Clot F, et al. Myoclonus-dystonia: an update. Mov Disord 2009; 24:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/25\">",
"      Roze E, Apartis E, Clot F, et al. Myoclonus-dystonia: clinical and electrophysiologic pattern related to SGCE mutations. Neurology 2008; 70:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/26\">",
"      Raymond D, Saunders-Pullman R, de Carvalho Aguiar P, et al. Phenotypic spectrum and sex effects in eleven myoclonus-dystonia families with epsilon-sarcoglycan mutations. Mov Disord 2008; 23:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/27\">",
"      Foncke EM, Gerrits MC, van Ruissen F, et al. Distal myoclonus and late onset in a large Dutch family with myoclonus-dystonia. Neurology 2006; 67:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/28\">",
"      Kurlan R, Behr J, Medved L, Shoulson I. Myoclonus and dystonia: a family study. Adv Neurol 1988; 50:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/29\">",
"      Quinn NP. Essential myoclonus and myoclonic dystonia. Mov Disord 1996; 11:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/30\">",
"      Asmus F, Gasser T. Inherited myoclonus-dystonia. Adv Neurol 2004; 94:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/31\">",
"      Han F, Lang AE, Racacho L, et al. Mutations in the epsilon-sarcoglycan gene found to be uncommon in seven myoclonus-dystonia families. Neurology 2003; 61:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/32\">",
"      Sch&uuml;le B, Kock N, Svetel M, et al. Genetic heterogeneity in ten families with myoclonus-dystonia. J Neurol Neurosurg Psychiatry 2004; 75:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/33\">",
"      Tezenas du Montcel S, Clot F, Vidailhet M, et al. Epsilon sarcoglycan mutations and phenotype in French patients with myoclonic syndromes. J Med Genet 2006; 43:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/34\">",
"      Ritz K, Gerrits MC, Foncke EM, et al. Myoclonus-dystonia: clinical and genetic evaluation of a large cohort. J Neurol Neurosurg Psychiatry 2009; 80:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/35\">",
"      Grimes DA, Han F, Lang AE, et al. A novel locus for inherited myoclonus-dystonia on 18p11. Neurology 2002; 59:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/36\">",
"      Stamelou M, Mencacci NE, Cordivari C, et al. Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. Neurology 2012; 79:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/37\">",
"      Saunders-Pullman R, Shriberg J, Heiman G, et al. Myoclonus dystonia: possible association with obsessive-compulsive disorder and alcohol dependence. Neurology 2002; 58:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/38\">",
"      Hess CW, Raymond D, Aguiar Pde C, et al. Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology 2007; 68:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/39\">",
"      Asmus F, Salih F, Hjermind LE, et al. Myoclonus-dystonia due to genomic deletions in the epsilon-sarcoglycan gene. Ann Neurol 2005; 58:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/40\">",
"      M&uuml;ller B, Hedrich K, Kock N, et al. Evidence that paternal expression of the epsilon-sarcoglycan gene accounts for reduced penetrance in myoclonus-dystonia. Am J Hum Genet 2002; 71:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/41\">",
"      Chan P, Gonzalez-Maeso J, Ruf F, et al. Epsilon-sarcoglycan immunoreactivity and mRNA expression in mouse brain. J Comp Neurol 2005; 482:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/42\">",
"      Thomas JE, Reagan TJ, Klass DW. Epilepsia partialis continua. A review of 32 cases. Arch Neurol 1977; 34:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/43\">",
"      Delgado-Escueta AV, Medina MT, Bai DS, et al. Genetics of idiopathic myoclonic epilepsies: an overview. Adv Neurol 2002; 89:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/44\">",
"      Kanai K, Hirose S, Oguni H, et al. Effect of localization of missense mutations in SCN1A on epilepsy phenotype severity. Neurology 2004; 63:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/45\">",
"      Striano P, Zara F, Striano S. Autosomal dominant cortical tremor, myoclonus and epilepsy: many syndromes, one phenotype. Acta Neurol Scand 2005; 111:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/46\">",
"      van Rootselaar AF, van Schaik IN, van den Maagdenberg AM, et al. Familial cortical myoclonic tremor with epilepsy: a single syndromic classification for a group of pedigrees bearing common features. Mov Disord 2005; 20:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/47\">",
"      Coppola A, Santulli L, Del Gaudio L, et al. Natural history and long-term evolution in families with autosomal dominant cortical tremor, myoclonus, and epilepsy. Epilepsia 2011; 52:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/48\">",
"      Alvarez M, Caviness JN. Primary progressive myoclonus of aging. Mov Disord 2008; 23:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/49\">",
"      Russell JF, Steckley JL, Coppola G, et al. Familial cortical myoclonus with a mutation in NOL3. Ann Neurol 2012; 72:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7689/abstract/50\">",
"      Shibasaki H, Hallett M. Electrophysiological studies of myoclonus. Muscle Nerve 2005; 31:157.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4885 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_32_7689=[""].join("\n");
var outline_f7_32_7689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMIC AND PHYSIOLOGIC CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cortical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cortical-subcortical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Subcortical-nonsegmental",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Segmental",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Peripheral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL AND ETIOLOGIC CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Physiologic myoclonus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Jerks associated with sleep",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Essential myoclonus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Palatal myoclonus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hereditary essential myoclonus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Myoclonus-dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Epileptic myoclonus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Fragments of epilepsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Myoclonic epilepsy syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Familial cortical myoclonic tremor with epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34491582\">",
"      Primary myoclonus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34491589\">",
"      - Primary progressive myoclonus of aging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34491596\">",
"      - Familial cortical myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Symptomatic (secondary) myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Syndrome identification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Clinical neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Findings associated with major anatomic-physiologic categories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Testing for rare causes of myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4885\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4885|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/18/27948\" title=\"table 1\">",
"      Anatomic physiologic classification myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/60/21455\" title=\"table 2\">",
"      Clinical etiologic classification myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/40/27277\" title=\"table 3\">",
"      Evaluation myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/18/23852\" title=\"table 4\">",
"      Clin neurophys myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/33/34333\" title=\"table 5\">",
"      Clinical features myoclonus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29832?source=related_link\">",
"      Huntington disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15849?source=related_link\">",
"      Juvenile myoclonic epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2754?source=related_link\">",
"      Patient information: Myoclonus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=related_link\">",
"      Symptomatic (secondary) myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=related_link\">",
"      Tests used in the diagnosis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6537?source=related_link\">",
"      Treatment of myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11833?source=related_link\">",
"      Whipple's disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_32_7690="Treatment of genital herpes simplex virus infection";
var content_f7_32_7690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of genital herpes simplex virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/32/7690/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/32/7690/contributors\">",
"     Mary A Albrecht, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/32/7690/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/32/7690/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/32/7690/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/32/7690/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/32/7690/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genital herpes simplex is a common sexually transmitted virus infection that is found worldwide. Most of these genital infections are caused by herpes simplex virus-2 (HSV-2), but herpes simplex virus-1 (HSV-1) also produces a clinically similar disease. Antiviral therapy can shorten the duration of symptoms and signs in primary infection which, when untreated, can be associated with significant morbidity. Clinical recurrences are also common and can be treated episodically or prevented with continual antiviral suppression.",
"   </p>",
"   <p>",
"    This topic review addresses the natural history of genital HSV infection, clinical recurrences, and data supporting treatment efficacy of primary and repeated episodes of infection. The epidemiology, clinical manifestations, and diagnosis of genital HSV infection and issues related to pregnancy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33001?source=see_link\">",
"     \"Genital herpes simplex virus infection and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21751?source=see_link\">",
"     \"Prevention of genital herpes virus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Primary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;An HSV outbreak is defined as \"primary\" if the patient was HSV-seronegative for both HSV-1 and HSV-2 before the episode of genital lesions. The primary episode of genital HSV infection can be associated with a multitude of constitutional symptoms and signs, such as fever, malaise, and headache. In addition to painful genital lesions, dysuria can be severe. Symptoms may last two to four weeks if left untreated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33001?source=see_link\">",
"     \"Genital herpes simplex virus infection and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonprimary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonprimary episode infection refers to HSV-2 infection in a person with preexisting HSV-1 immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/1\">",
"     1",
"    </a>",
"    ]. The signs and symptoms of primary infection tend to be less severe than in the person without any existing HSV antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Recurrent symptomatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although treatment during primary infection lessens morbidity, it does not eradicate latent virus, which can subsequently reactivate. Genital HSV infection often leads to frequent clinical recurrences, although the risk of genital recurrence is lower in those infected with HSV-1 versus HSV-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/2\">",
"     2",
"    </a>",
"    ]. In the absence of suppressive antiviral therapy, the median recurrence rate after the first episode of HSV-2 infection is about four recurrences a year, with about 40 percent of patients having at least six recurrences and 20 percent having more than 10 recurrences in the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. In contrast, recurrences of HSV-1 occur much less frequently (approximately once per year). Over time, recurrences due to either viral type generally decrease in number and severity, although there is substantial variability in the clinical course from patient to patient [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With recurrent infection, genital lesions may be asymptomatic, few in number, or atypical in appearance, especially in women (eg, fissures or vulvar irritation). In addition, the mean duration of lesions is shorter than that seen with the primary episode (10 versus 19 days) and the duration of viral shedding is shorter (two versus nine days) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/5\">",
"     5",
"    </a>",
"    ]. Finally, antiviral therapy does not eradicate latent HSV infection and thus does not change the frequency or severity of recurrences, once therapy is stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/1,2,4\">",
"     1,2,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'Recurrent infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These concepts were well illustrated in an observational cohort study of 664 immunocompetent patients with genital HSV-1 or HSV-2 infection who were followed for a minimum of 14 months; 306 had newly-acquired infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/4\">",
"     4",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with newly acquired genital herpes, the median rate of recurrence in the first year was lower in patients with HSV-1 compared with HSV-2 infection (one versus five per year, respectively). Second year rates were lower in both groups.",
"     </li>",
"     <li>",
"      Patients infected with HSV-2 who were followed for more than four years had a decreased recurrence rate over time. However, about one-fourth of patients experienced an increase in recurrences at the five-year follow-up, highlighting the variability in disease course among HSV-2-infected persons.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ANTIVIRAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed in detail in the next section,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    appear to have similar efficacy for the treatment of primary genital herpes and for the suppression of recurrent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Famciclovir and valacyclovir have greater oral bioavailability than acyclovir. Topical therapy is of marginal benefit and should not be used [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/8\">",
"     8",
"    </a>",
"    ]. The margin of safety and tolerability of all three medications is excellent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT OF PRIMARY HSV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary HSV infection can cause prolonged clinical illness with severe genital ulcerations. Thus, all patients with a suspected primary episode of HSV should be treated with antiviral therapy. Initiation of oral antiviral therapy within 72 hours of lesion appearance may decrease duration and severity of illness by days to weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/9\">",
"     9",
"    </a>",
"    ]. Furthermore, antiviral therapy can decrease the risk of complicated primary infection (eg, meningitis or sacral radiculitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Complicated HSV'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    All of the available agents (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    ) are efficacious in the treatment of primary genital HSV infection. The dosing frequency varies from agent to agent. Multiple trials have been conducted to determine the shortest duration of therapy that may be effective in achieving symptomatic relief. Oral therapy is usually adequate, except in cases of complicated HSV infection. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Complicated HSV'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following is a survey of the major clinical trials that have assessed the efficacy of antiviral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acyclovir versus placebo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most data on the treatment of primary genital herpes come from studies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/5,11,12\">",
"     5,11,12",
"    </a>",
"    ]. In a randomized, controlled trial, 48 patients with a first episode of genital herpes were assigned to acyclovir (200 mg) or placebo five times daily for ten days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/11\">",
"     11",
"    </a>",
"    ]. Acyclovir significantly reduced pain, length of time to healing, and duration of viral shedding. Similar benefits, including resolution of constitutional symptoms, were associated with acyclovir use in another placebo-controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Famciclovir versus acyclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     Famciclovir",
"    </a>",
"    , the oral prodrug of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"     penciclovir",
"    </a>",
"    , has increased bioavailability as well as a substantially longer half-life compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    . This allows for less frequent dosing of famciclovir compared with acyclovir.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     Famciclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    have comparable efficacy for the treatment of primary genital HSV. In three separate double-blind controlled studies, several different dosing regimens of famciclovir (125, 250, 500, 750 mg) were compared with acyclovir for either 5 or 10 days of dosing in a total of 951 patients; one-third of the enrolled patients had primary HSV [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/13\">",
"     13",
"    </a>",
"    ]. Famciclovir was given three times daily and acyclovir was given five times daily. Duration of shedding, median time to lesion healing, and time to resolution of symptoms were comparable among the famciclovir and acyclovir arms. In the 10-day study, the 125 mg famciclovir arm was not as effective as the other doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Valacyclovir versus acyclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    appear equally efficacious, although valacyclovir affords less frequent dosing. In a large multicenter, comparative, randomized trial, 643 adults with a first episode of genital herpes were assigned to 10 days of therapy with acyclovir (200 mg PO five times daily) or valacyclovir (1000 mg PO twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/14\">",
"     14",
"    </a>",
"    ]. There were no significant differences between the regimens in time to healing, duration of pain, time to clearing of all symptoms, and duration of viral shedding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Valacyclovir versus famciclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;No studies have directly compared these two agents for the first episode of genital HSV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Complicated HSV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral therapy may be required in patients with primary genital herpes infections accompanied by more severe clinical manifestations, such as [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central nervous system disease, such as aseptic meningitis, encephalitis, or transverse myelitis",
"     </li>",
"     <li>",
"      End organ disease including hepatitis or pneumonitis",
"     </li>",
"     <li>",
"      Disseminated HSV",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dose of IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    and the specific duration of therapy are not well delineated based on a lack of clinical trials; treatment should be individually tailored to the specific clinical setting. In patients with complicated HSV infection, the Centers for Disease Control and Prevention (CDC) recommends intravenous acyclovir (5 to10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight hours for two to seven days or longer until clinical improvement is documented, followed by transition to oral antiviral therapy to complete at least 10 days of therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15417?source=see_link&amp;anchor=H6#H6\">",
"     \"Aseptic meningitis in adults\", section on 'Herpes simplex meningitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'Extragenital complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunocompromised patients may have a more severe and protracted course and may require longer therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Adjunctive therapy for primary HSV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with a primary episode of genital HSV experience moderate to severe local pain in the affected genital or sacral areas. Analgesics may be required in severe primary episodes with multiple painful lesions. Sitz baths are often helpful for women with severe dysuria secondary to multiple ulcerations.",
"   </p>",
"   <p>",
"    A woman who complains of difficulty urinating may have developed urinary retention secondary to sacral nerve root involvement. In this clinical situation, either intermittent or indwelling bladder catheterization may also be required, usually for several days, but occasionally extending beyond one week. Administration of pain medications prior to catheter insertion helps to decrease discomfort associated with the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Timing of initiation of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt initiation of therapy is important to obtain maximal clinical benefit. Most studies have evaluated drug initiation within 72 hours of onset of clinical symptoms; however, if a patient presents after this time frame with ongoing development of new lesions and significant pain, antiviral therapy should still be offered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Summary for primary genital HSV treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with untreated disease, oral antiviral therapy significantly decreases the duration and severity of disease with minimal adverse drug effects. We therefore recommend oral antiviral therapy for the treatment of uncomplicated primary genital HSV infection. Any of the three available agents can be used in this setting, since they all appear equally effective [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/12,15-17\">",
"     12,15-17",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    is given less frequently than the others, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is much less expensive. The usual duration of treatment is 7 to 10 days.",
"   </p>",
"   <p>",
"    We agree with the 2010 Centers for Disease Control and Prevention guidelines, which recommend the following treatment options [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      : 400 mg PO three times per day or 200 mg PO five times per day",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       Famciclovir",
"      </a>",
"      : 250 mg PO three times daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      : 1000 mg PO twice daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT STRATEGIES FOR RECURRENT DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Therapeutic options",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with recurrent genital HSV, factors that influence the management strategy include the frequency of recurrent episodes, severity of symptoms and signs, and risk of viral transmission to an uninfected sexual partner. Clinicians and patients alike need to also be aware that viral shedding can occur despite complete absence of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link&amp;anchor=H16#H16\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'Viral shedding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific options include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic suppressive therapy: This strategy involves the administration of daily antiviral therapy, which may be most appropriate for those with very frequent recurrences or HSV-seropositive patients with uninfected sexual partners.",
"     </li>",
"     <li>",
"      Episodic therapy: This approach involves self-administered antiviral therapy for individual outbreaks as they arise. Patients should be counseled to start therapy at the very first sign of prodromal symptoms (eg, tingling, paresthesias, pruritis), which may occur prior to onset of discrete lesions.",
"     </li>",
"     <li>",
"      No intervention: No therapeutic intervention may be appropriate for some patients, particularly those with infrequent episodes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      minimal symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Comparisons between episodic and suppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on the optimal treatment strategy, each of which has its advantages and disadvantages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Clinical benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;One early placebo-controlled trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    in 156 patients with frequent recurrences (more than six per year) compared suppressive therapy (400 mg twice daily) to episodic therapy (200 mg five times daily) for five days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/18\">",
"     18",
"    </a>",
"    ]. The trial results demonstrated that suppressive therapy was superior compared with the other arms in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reducing the median time to recurrence (250, 28, and 23 days for patients in the suppressive, episodic, and placebo arms, respectively)",
"     </li>",
"     <li>",
"      Reducing the median number of days per month with active disease (0.32, 4.18 and 4.72 days for the suppressive, episodic, and placebo arms, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quality of life measures appear to be superior with chronic suppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. This was shown in a multicenter, open-label, randomized, two-arm, crossover study involving 225 patients, in which the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    for episodic (500 mg twice daily for five days) versus suppressive therapy (500 mg daily) was evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/20\">",
"     20",
"    </a>",
"    ]. The mean number of recurrences prior to study entry was approximately six per year. The study demonstrated the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The probability of developing a recurrence was 78 percent lower in patients assigned to the suppressive therapy arm than to the episodic arm.",
"     </li>",
"     <li>",
"      No serious drug toxicity was reported over the 48-week period of the study.",
"     </li>",
"     <li>",
"      Of the 202 patients who completed the 48-week study, patient preference strongly favored suppressive versus episodic therapy (72 versus 28 percent). Treatment satisfaction (as measured by a disease-specific validated questionnaire) was based on various factors, such as perceived drug effectiveness, convenience, and lifestyle effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Patient considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of episodic versus chronic suppressive therapy should also be individualized based on patient preference [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Frequency of recurrences",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with recurrent HSV, decisions regarding suppressive versus episodic therapy are strongly influenced by the frequency and severity of the clinical episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients may find chronic suppressive therapy burdensome due to the need for daily adherence to their medication schedule. Improvements in the dosing and duration of episodic therapy have made this type of intervention more attractive than previous regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Psychosocial considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are also psychological aspects of recurrent genital HSV that can be distressing for some patients, which may be under-appreciated by the clinician. It is important to openly address these patient concerns and to offer counseling regarding the natural history of disease and transmission risk. In patients who experience considerable anxiety or distress, chronic suppressive therapy may be preferable, even in those with less frequent outbreaks. Patient preference should be strongly factored into these treatment decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    is extremely well tolerated during primary and episodic therapy. Although studies of chronic suppressive therapy have not shown significant toxicity, most studies have had limited long-term follow-up of one year or less [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/22\">",
"     22",
"    </a>",
"    ] with few exceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Cost of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic suppressive therapy is much more expensive than episodic therapy and may not be covered by all medical insurance providers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Risk of transmission to uninfected partner",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients will primarily choose chronic suppressive therapy to decrease the risk of transmission of HSV to their uninfected sexual partner. Others may prefer to address this risk with consistent condom use.",
"   </p>",
"   <p>",
"    Data regarding these two main strategies are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     EPISODIC TREATMENT OF RECURRENT GENITAL HERPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent episodes of genital HSV tend to be less severe and of shorter duration.",
"   </p>",
"   <p>",
"    Antiviral therapy for recurrent episodes can be dispensed either episodically to address active lesions as they occur, or continuously as suppressive therapy. The most important measures of efficacy of episodic therapy include the duration of both lesions and symptoms, as well as the proportion of aborted episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/24\">",
"     24",
"    </a>",
"    ]. Compared with suppressive therapy, episodic therapy is less costly and is not dependent on medication adherence to a daily regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No study has explicitly examined the benefits versus adverse effects of antiviral therapy based upon the frequency of recurrence. The threshold level of six or more lesions per year is largely arbitrary, but is based upon the perceived modest benefits with antiviral therapy. Patient preference is clearly an important factor in determining treatment strategy. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Suppressive therapy for recurrent genital herpes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is also important to realize that a number of patients may have few, if any, recurrent episodes of genital herpes. Such patients may not require antiviral therapy, particularly those with very mildly symptomatic disease or those who are not sexually active.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Importance of timing of therapy for episodic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;When used as episodic therapy, one early study demonstrated that the greatest benefit of antiviral therapy was derived by patients who self-initiated therapy compared with those who started treatment within 48 hours of lesion appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/25\">",
"     25",
"    </a>",
"    ]. Subsequent studies of all three anti-herpes agents demonstrated that early initiation of therapy (within 24 hours of symptoms) leads to faster resolution of recurrent cutaneous lesions and clinical symptoms compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/9,25\">",
"     9,25",
"    </a>",
"    ]. Earlier trials generally used five days of episodic treatment, while later trials evaluated the efficacy of shorter courses of therapy (ie, one to three days) to improve patient convenience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies of episodic treatment utilized five days of antiviral therapy; however, subsequent studies have demonstrated that patients treated with high-dose antiviral medications for only one to three days have similar clinical benefits as those treated three times daily for the standard five-day regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]. Brief courses of antiviral medications offer improved patient convenience.",
"   </p>",
"   <p>",
"    Data on these individual agents are found below. Chronic suppression of recurrence is discussed in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Acyclovir versus placebo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with placebo,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    modestly shortens the time to crusting and healing of lesions and also decreases the duration of viral shedding [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. This was shown in a study in which 131 patients with recurrent infections were randomly assigned to 800 mg of acyclovir three times daily for two days or placebo; treatment was begun within 12 hours of first signs or symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/26\">",
"     26",
"    </a>",
"    ]. Compared with placebo, acyclovir was associated with more rapid healing of lesions (four versus six days) and decreased duration of viral shedding (25 versus 59 hours). Acyclovir therapy was also associated with a higher proportion of aborted clinical HSV episodes (ie, those lesions never progressing past a papule).",
"   </p>",
"   <p>",
"    The optimal dosing regimen for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is unclear. Similar efficacy has been reported with 800 mg three times daily for two days, 200 mg five times daily for five days, or 800 mg twice daily for five days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, 800 mg twice daily for five days appears to have greater efficacy in men compared with other regimens, even when initiated after the prodromal period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Famciclovir versus placebo",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    for recurrent episodes of genital HSV was illustrated in a multicenter trial of patient-initiated treatment with either famciclovir (125, 250 or 500 mg twice daily for five days) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/28\">",
"     28",
"    </a>",
"    ]. Subjects were instructed to perform cultures and to start therapy within six hours of lesion or symptom onset.",
"   </p>",
"   <p>",
"    Compared with placebo, each",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    dose produced a significant acceleration in cutaneous healing and symptom resolution (by approximately one day) and cessation of viral shedding (by approximately two days). There was no difference with respect to lesion healing among the famciclovir dosage arms. A subsequent randomized controlled trial demonstrated that a two-day short-course regimen of famciclovir (500 mg initially, then 250 mg twice daily) was non-inferior to five days of famciclovir [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of a shorter course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    (two 1000 mg doses on a single day) was evaluated for episodic treatment of genital HSV in immunocompetent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/29\">",
"     29",
"    </a>",
"    ]. In this multicenter, double-blind, placebo-controlled trial of 329 patients, famciclovir resulted in a faster median healing time compared with placebo (4.3 versus 6.1 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/29\">",
"     29",
"    </a>",
"    ]. Furthermore, the proportion of patients with aborted lesions was greater in the famciclovir group than in the placebo group (23 versus 13 percent). These preliminary data suggest that early, high-dose antiviral therapy for a brief duration of time may also be a potential therapeutic option. One-day therapy with famciclovir was also shown to be non-inferior to three days of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Head-to-head comparisons'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Valacyclovir versus placebo",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    shortens healing time and accelerates resolution of pain by one to two days compared with untreated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Three days of treatment with valacyclovir was also found to be equivalent to five days of valacyclovir in terms of healing, viral shedding, and lesion abortion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Head-to-head comparisons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few direct drug-to-drug comparisons have been conducted for the treatment of recurrent HSV:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 739 patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (500 mg PO twice daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (200 mg PO five times daily) for five days at the time of the next recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/35\">",
"       35",
"      </a>",
"      ]. There was no difference between the groups in the primary end point, which was the duration of all signs and symptoms, including lesion healing and pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      discomfort.",
"      <br/>",
"      <br/>",
"      Percentages of patients in whom all HSV cultures were negative were similar in the valacyclovir and acyclovir groups (59 and 54 percent, respectively). In patients with a positive culture before treatment, cessation of viral shedding was similarly rapid in both groups.",
"     </li>",
"     <li>",
"      In a non-inferiority study of 1179 adults with a history of recurrent genital HSV, single-day",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      (1000 mg twice daily) was compared with a three-day course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (500 mg twice daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/30\">",
"       30",
"      </a>",
"      ]. Mean time to healing of lesions was similar in both groups and approximately one-third of patients in each treatment arm had aborted episodes. Both regimens were well tolerated. Viral shedding was not evaluated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Treatment recommendations for episodic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend individualization of treatment, after discussion of the pros and cons of therapy with each patient. Antiviral therapy may be useful for the treatment of recurrent genital lesions in patients with fewer than six episodes annually to decrease the duration of signs and symptoms associated with HSV infection and to decrease the duration of viral shedding. However, alternative strategies include no treatment or chronic suppressive therapy, as discussed above. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment strategies for recurrent disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although few head-to-head comparisons have been performed, all available antiviral therapies appear to be similarly efficacious. Single-day therapy is an option with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    (1000 mg twice daily), which has been compared with a three-day course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (500 mg twice daily) with similar efficacy. If cost is a significant issue,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is generally less expensive, although it requires more frequent dosing and a longer duration of therapy. Some patients may prefer less frequent daily dosing and a longer duration of therapy, while others may prefer a shorter course of therapy.",
"   </p>",
"   <p>",
"    Regardless of the antiviral agent used, treatment of recurrent episodes is associated with faster resolution of cutaneous lesions and clinical symptoms if initiated within the first 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/25,26,28\">",
"     25,26,28",
"    </a>",
"    ]. This is easiest to achieve if the patient is given a supply of medication, and therapy is initiated by the patient at the first sign of recurrence. It is important to counsel the patient that symptoms of recurrence can include tingling or paresthesias prior to the development of discrete lesions.",
"   </p>",
"   <p>",
"    We agree with the 2010 Centers for Disease Control and Prevention guidelines, which recommend the following treatment options for episodic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      : 800 mg PO three times daily for two days or 800 mg PO twice daily for five days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       Famciclovir",
"      </a>",
"      : 1000 mg PO twice daily for a single day duration or 125 mg PO twice daily for five days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      : 500 mg PO twice daily for three days or 1 gram orally for five days",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUPPRESSIVE THERAPY FOR RECURRENT GENITAL HERPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppressive therapy for recurrent genital herpes involves the administration of daily chronic therapy, which reduces viral shedding [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/36\">",
"     36",
"    </a>",
"    ]. Studies of suppressive therapy for recurrent HSV have assessed efficacy according to time to first recurrence, frequency of recurrences, severity and duration of recurrences, viral shedding, and frequency of recurrences after treatment. Of these, the most reliable clinical measures of antiviral benefit include the time to first recurrence and frequency of recurrences over time [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have demonstrated that approximately half of patients on suppressive therapy remain recurrence-free and other patients have a significant reduction in frequency of recurrences (70 to 80 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/9,37\">",
"     9,37",
"    </a>",
"    ]. Chronic suppressive therapy is usually offered to patients who experience six or more clinical episodes per year or who experience significant anxiety or distress related to their clinical recurrences. Suppressive therapy also decreases the risk of transmission to an uninfected sexual partner. (See",
"    <a class=\"local\" href=\"#H43\">",
"     'Valacyclovir use in discordant couples'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The safety of long-term therapy has been demonstrated over six years of continuous treatment in one study of 239 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/23\">",
"     23",
"    </a>",
"    ]. However, as noted above, in the natural course of disease, the number of recurrences diminishes with time, whether or not antiviral therapy is administered [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/38\">",
"     38",
"    </a>",
"    ]. Therefore, many experts recommend treatment discontinuation to evaluate the ongoing need for suppressive antiviral therapy on an annual basis to evaluate disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/39\">",
"     39",
"    </a>",
"    ]. However, some patients may not desire treatment discontinuation due to concerns about severity of recurrent lesions during treatment interruption, which has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative efficacy of the available antiviral medications for suppression of genital herpes has been analyzed in a large meta-analysis of 6158 immunocompetent patients from 14 randomized placebo-controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/22\">",
"     22",
"    </a>",
"    ]. Compared with placebo, suppressive antiviral therapy lowered the relative risk of developing at least one recurrence (RR of 47 percent, 95% CI of 45-49 percent). This meta-analysis demonstrated comparable efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (400 mg twice daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (250 mg twice daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    (250 mg twice daily), or once-daily valacyclovir (500 mg). Limitations of this meta-analysis include heterogeneity of dosing regimens, varying rates of follow-up, and different methods for detection of shedding. Cost and potential long-term risks of chronic therapy were not addressed.",
"   </p>",
"   <p>",
"    Data on the individual agents are discussed below; most cited studies are randomized placebo-controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Acyclovir versus placebo",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    has demonstrated clinical benefit in patients with frequent clinical disease (eg, six or more episodes per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In the largest randomized placebo-controlled trial, four months of suppressive therapy with acyclovir (either 200 mg five times daily or 200 mg twice daily) markedly reduced the frequency of clinical recurrence and of asymptomatic viral shedding compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/41\">",
"     41",
"    </a>",
"    ]. The median time to the first clinical recurrence was 18 days in placebo recipients, compared with over 120 days (ie, after suppression was stopped) in both acyclovir-treated groups. Another study evaluated a dosing regimen of 400 mg twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Famciclovir versus placebo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppressive treatment with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    also prolongs the interval to recurrence of symptomatic episodes and decreases viral shedding [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. A multicenter trial was conducted in which 375 women with a history of at least six recurrences over 12 of the previous 24 months were randomly assigned to placebo or oral famciclovir (125 mg once or twice daily, 250 mg once or twice daily, or 500 mg once daily) for a four-month period [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/43\">",
"     43",
"    </a>",
"    ]. Famciclovir (250 mg twice daily) was the most effective of the regimens, prolonging the time to first recurrence (120 versus 82 days with placebo) and increasing the likelihood of remaining free of clinically confirmed genital HSV outbreaks (78 versus 42 percent). Once-daily famciclovir regimens were less effective than twice-daily regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Valacyclovir versus placebo",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    is also effective in reducing clinical recurrences and asymptomatic viral shedding with 500 mg dosing once daily [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/36,45\">",
"     36,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a placebo-controlled trial, 382 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (500 mg daily) or placebo in a 3:1 ratio for 16 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/45\">",
"     45",
"    </a>",
"    ]. After 16 weeks (day 112) with treatment, 69 percent of patients receiving valacyclovir were recurrence-free compared with only 9.5 percent of patients assigned to placebo.",
"   </p>",
"   <p>",
"    In another randomized placebo-controlled trial, which was primarily designed to assess the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    on transmission rates in discordant couples, those patients receiving suppressive therapy had significant treatment benefits that included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fewer days of viral shedding (2.9 versus 10.8 percent of days) and fewer recurrences of genital herpes (0.11 versus 0.40 per month)",
"     </li>",
"     <li>",
"      A reduction in the incidence of clinically symptomatic genital HSV-2 infections (0.5 versus 2.2 percent with placebo, hazard ratio 0.25, 95% CI 0.08-0.75).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    was also associated with decreased rates of HSV transmission to the uninfected partner. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21751?source=see_link&amp;anchor=H10#H10\">",
"     \"Prevention of genital herpes virus infections\", section on 'Chronic suppressive therapy in discordant couples'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Head-to-head comparison trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few comparative studies have assessed the efficacy of these various agents head-to-head.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    appear to provide similar benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Valacyclovir versus famciclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized, double-blind, placebo-controlled studies comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    250 mg twice daily with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    500 mg once daily for 16 weeks demonstrated the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The time to first clinical recurrence while on treatment among 320 patients was similar in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      recipients, but the time to the first virologically confirmed recurrence was shorter among famciclovir recipients, HR = 2.15 (95% CI, 1.00-4.60).",
"     </li>",
"     <li>",
"      In a second 10-week study of 70 patients, HSV was detected on 3.2 percent of days among",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      recipients and 1.3 percent of days among",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      recipients during therapy (RR 2.33; 95% CI, 1.18-4.89).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Valacyclovir versus acyclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized double-blind study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    was performed to evaluate the efficacy of valacyclovir versus placebo or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    in 1479 patients with frequent recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/37\">",
"     37",
"    </a>",
"    ]. Subjects were randomly assigned to receive valacyclovir (250 mg, 500 mg, or 1000 mg once daily, or 250 mg twice daily), acyclovir (400 mg twice daily), or placebo, for one year.",
"   </p>",
"   <p>",
"    All subjects in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    arms had significantly lower rates of recurrences compared with those receiving placebo. There was a dose-response relationship across all of the valacyclovir arms. Subjects assigned to twice-daily dosing of valacyclovir or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    had similar rates of recurrence. A subset analysis suggested that higher doses of valacyclovir (500 mg) were more effective than lower doses in subjects with &ge;10 recurrences per year.",
"   </p>",
"   <p>",
"    One randomized, double-blind, crossover trial specifically addressed the issue of subclinical viral shedding with placebo compared with therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (500 mg twice daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (400 mg twice daily) in 69 subjects with genital HSV-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/47\">",
"     47",
"    </a>",
"    ]. Subjects were instructed to collect daily genital specimens that were evaluated by culture and polymerase chain reaction. Valacyclovir and acyclovir were similarly effective; HSV was isolated in culture on 15 percent of the days while receiving placebo, compared with 0.5 percent of days on valacyclovir and 0.8 percent of days on acyclovir, a reduction of 97 percent and 95 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Valacyclovir use in discordant couples",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppressive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    is also beneficial in decreasing transmission to an uninfected sexual partner. This was demonstrated in a large randomized placebo-controlled trial of 1484 immunocompetent, heterosexual, discordant couples [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/36\">",
"     36",
"    </a>",
"    ]. Partners with HSV-2 infection were randomly assigned to receive either 500 mg of valacyclovir once daily or placebo for eight months; the susceptible partner was evaluated monthly for clinical signs and symptoms of genital herpes. Suppressive therapy led to a relative reduction in overall acquisition of genital HSV-2 infection in the uninfected partner (1.9 versus 3.6 percent, hazard ratio 0.52, 95% CI 0.27-0.99). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21751?source=see_link\">",
"     \"Prevention of genital herpes virus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Treatment recommendations for suppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral therapy effectively suppresses HSV reactivation and decreases shedding in patients with frequent recurrences. Discussions regarding long-term suppressive therapy should include disease activity, presence of psychosexual morbidity, need for drug adherence, potential toxicity of chronic therapy, and cost.",
"   </p>",
"   <p>",
"    Given that all approved anti-herpes agents are similarly effective, the choice of agent is principally influenced by dosing frequency and cost. One direct comparative study suggested modestly increased efficacy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    , when dosed once daily [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/46\">",
"     46",
"    </a>",
"    ]. In addition, suppressive therapy with valacyclovir has also decreased transmission in discordant sexual partners. In the patient with frequent recurrences who is sexually active with an uninfected partner, we suggest valacyclovir 500 mg once daily as the preferred agent.",
"   </p>",
"   <p>",
"    Although suppressive therapy has been given for as long as six years, the use of suppressive antiviral medications should be re-evaluated periodically, since the benefits and risks beyond six years have not yet been determined [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the 2010 Centers for Disease Control and Prevention guidelines, which recommend the following treatment options [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      : 400 mg twice daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       Famciclovir",
"      </a>",
"      : 250 mg PO two times daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      : 500 mg once daily OR 1 gram orally once a day",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      is used, the 1 gram dose is recommended among patients with &gt;10 recurrences annually [",
"      <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     CHRONIC SUPPRESSIVE THERAPY FOR DISCORDANT COUPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed discussion of the use of chronic suppressive therapy for discordant couples is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21751?source=see_link\">",
"     \"Prevention of genital herpes virus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9186033\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS IN HIV-INFECTED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompromised patients with HIV may have prolonged or severe episodes of genital herpes. The initiation of antiretroviral therapy (ART) can reduce the severity and frequency of genital lesions secondary to HSV. The CDC recommends daily suppressive therapy for patients with frequent recurrences with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    at higher dosages than in HIV-uninfected patients as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      400 to 800 mg orally twice daily to three times daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       Famciclovir",
"      </a>",
"      500 mg orally twice daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      500 mg orally twice daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     ANTIVIRAL DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergence of clinical infection with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    -resistant HSV-2 during chronic suppressive therapy in immunocompetent patients is relatively rare [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/48-54\">",
"     48-54",
"    </a>",
"    ]. In two large series, the rate was 0.18 and 0.32 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/32/7690/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Even when drug-resistant HSV is isolated from an immunocompetent patient, this virus, with rare exceptions, is cleared normally without adverse clinical outcome.",
"   </p>",
"   <p>",
"    However, drug resistance has been observed in HIV-infected patients on long-term therapy. When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    drug resistance is confirmed, cross-resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    should be expected;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    may be effective for clinical management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link\">",
"     \"Foscarnet: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms of resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    and related compounds are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9186078\">",
"    <span class=\"h1\">",
"     PATIENT COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of counseling the patient and their sex partners is to help the patient cope with their diagnosis, prevent transmission, and identify any concerns or misconceptions. Patients need to be educated about the natural history of their infection with emphasis on viral shedding, the potential for clinical recurrence and sexual transmission even when asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=see_link\">",
"       \"Patient information: Genital herpes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/3/36916?source=see_link\">",
"       \"Patient information: Genital herpes (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genital herpes simplex virus infection is a common sexually transmitted disease that is found worldwide. After the primary episode, genital HSV infection can recur frequently in a subset of patients, particularly those infected with HSV-2. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Over time, clinical HSV recurrences generally decrease in frequency, although there is substantial variability in the clinical course from patient to patient. Antiviral therapy does not change the biology of latent HSV, whether given during the first episode of primary infection or during recurrent disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Natural history of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      all have similar antiviral activity against HSV, although famciclovir and valacyclovir have improved bioavailability versus acyclovir. Safety and tolerability are excellent with all three agents. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Antiviral agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with a primary episode of general HSV, we recommend antiviral therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Clinical trials have demonstrated comparable efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      ; the last has the convenience of twice-daily dosing. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment of primary HSV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with recurrent genital HSV, clinical considerations that influence the management strategy include the frequency of recurrent episodes and the severity of symptoms. Specific options include episodic therapy, chronic suppressive therapy, or no treatment.",
"     </li>",
"     <li>",
"      In a patient with frequent recurrent episodes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severely symptomatic recurrent disease, we suggest chronic suppressive antiviral therapy rather than episodic treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      offers the convenience of once-daily therapy in this situation.",
"     </li>",
"     <li>",
"      Among patients with less frequent recurrent episodes or moderately symptomatic disease, we suggest administration of episodic antiviral therapy rather than chronic suppression (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Clinical trials have demonstrated comparable efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      . Single-day therapy with famciclovir (1000 mg twice daily) is a convenient option with similar efficacy as a three-day course of valacyclovir (500 mg twice daily). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Episodic treatment of recurrent genital herpes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient preference must also be strongly considered in choosing between these treatment strategies. The presence of severe psychological stress related to HSV outbreaks may favor suppressive therapy, regardless of frequency, whereas the lower cost and convenience of short-term therapy may favor episodic treatment for some patients. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment strategies for recurrent disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No therapeutic intervention may be appropriate for some patients, particularly those with infrequent episodes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      minimal symptoms.",
"     </li>",
"     <li>",
"      Antiviral drug resistance is rare in the immunocompetent host. (See",
"      <a class=\"local\" href=\"#H46\">",
"       'Antiviral drug resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Options for prevention of viral transmission to a HSV-seronegative partner include antiviral therapy and barrier methods. This is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21751?source=see_link\">",
"       \"Prevention of genital herpes virus infections\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/1\">",
"      Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007; 370:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/2\">",
"      Corey L, Mindel A, Fife KH, et al. Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir. Sex Transm Dis 1985; 12:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/3\">",
"      Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983; 98:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/4\">",
"      Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med 1999; 131:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/5\">",
"      Mertz GJ, Critchlow CW, Benedetti J, et al. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA 1984; 252:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/6\">",
"      Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 1995; 50:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/7\">",
"      Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996; 52:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/8\">",
"      Corey L, Benedetti J, Critchlow C, et al. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. J Antimicrob Chemother 1983; 12 Suppl B:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/9\">",
"      Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med 2008; 168:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/10\">",
"      Corey L, Fife KH, Benedetti JK, et al. Intravenous acyclovir for the treatment of primary genital herpes. Ann Intern Med 1983; 98:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/11\">",
"      Bryson YJ, Dillon M, Lovett M, et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med 1983; 308:916.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/default.htm (Accessed on February 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/13\">",
"      Loveless M, Sacks SL, Harris JRW. Famciclovir in the management of first- episode genital herpes. Infect Dis Clin Pract 1997; 6:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/14\">",
"      Fife KH, Barbarash RA, Rudolph T, et al. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Sex Transm Dis 1997; 24:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/15\">",
"      Wald A, Benedetti J, Davis G, et al. A randomized, double-blind, comparative trial comparing high- and standard-dose oral acyclovir for first-episode genital herpes infections. Antimicrob Agents Chemother 1994; 38:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/16\">",
"      Drugs for sexually transmitted infections. Treat Guidel Med Lett 2004; 2:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/17\">",
"      Drugs for non-HIV viral infections. Treat Guidel Med Lett 2005; 3:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/18\">",
"      Mattison HR, Reichman RC, Benedetti J, et al. Double-blind, placebo-controlled trial comparing long-term suppressive with short-term oral acyclovir therapy for management of recurrent genital herpes. Am J Med 1988; 85:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/19\">",
"      Fife KH, Almekinder J, Ofner S. A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir. Sex Transm Dis 2007; 34:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/20\">",
"      Mills J, Mindel A. Genital herpes simplex infections: some therapeutic dilemmas. Sex Transm Dis 2003; 30:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/21\">",
"      Patel R, Stanberry L, Whitley RJ. Review of recent HSV recurrent-infection treatment studies. Herpes 2007; 14:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/22\">",
"      Lebrun-Vignes B, Bouzamondo A, Dupuy A, et al. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol 2007; 57:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/23\">",
"      Fife KH, Crumpacker CS, Mertz GJ, et al. Recurrence and resistance patterns of herpes simplex virus following cessation of &gt; or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group. J Infect Dis 1994; 169:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/24\">",
"      Corey L, Bodsworth N, Mindel A, et al. An update on short-course episodic and prevention therapies for herpes genitalis. Herpes 2007; 14 Suppl 1:5A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/25\">",
"      Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA 1984; 251:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/26\">",
"      Wald A, Carrell D, Remington M, et al. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002; 34:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/27\">",
"      Goldberg LH, Kaufman R, Conant MA, et al. Oral acyclovir for episodic treatment of recurrent genital herpes. Efficacy and safety. J Am Acad Dermatol 1986; 15:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/28\">",
"      Sacks SL, Aoki FY, Diaz-Mitoma F, et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA 1996; 276:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/29\">",
"      Aoki FY, Tyring S, Diaz-Mitoma F, et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2006; 42:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/30\">",
"      Abudalu M, Tyring S, Koltun W, et al. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. Clin Infect Dis 2008; 47:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/31\">",
"      Spruance SL, Tyring SK, DeGregorio B, et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med 1996; 156:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/32\">",
"      Saiag P, Praindhui D, Chastang C. A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. Genival Study Group. J Antimicrob Chemother 1999; 44:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/33\">",
"      Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 2002; 34:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/34\">",
"      Strand A, Patel R, Wulf HC, et al. Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir. Sex Transm Infect 2002; 78:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/35\">",
"      Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Genitourin Med 1997; 73:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/36\">",
"      Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/37\">",
"      Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. J Infect Dis 1998; 178:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/38\">",
"      Straus SE, Croen KD, Sawyer MH, et al. Acyclovir suppression of frequently recurring genital herpes. Efficacy and diminishing need during successive years of treatment. JAMA 1988; 260:2227.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/default.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/40\">",
"      Molin L, Ruhnek-Forsbeck M, Svennerholm B. One year acyclovir suppression of frequently recurring genital herpes: a study of efficacy, safety, virus sensitivity and antibody response. Scand J Infect Dis Suppl 1991; 80:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/41\">",
"      Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984; 310:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/42\">",
"      Mertz GJ. Management of genital herpes. Adv Exp Med Biol 1996; 394:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/43\">",
"      Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med 1997; 157:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/44\">",
"      Sacks SL. Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial. J Infect Dis 2004; 189:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/45\">",
"      Patel R, Bodsworth NJ, Woolley P, et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. Genitourin Med 1997; 73:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/46\">",
"      Wald A, Selke S, Warren T, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis 2006; 33:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/47\">",
"      Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004; 190:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/48\">",
"      Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998; 26:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/49\">",
"      Balfour HH Jr. Resistance of herpes simplex to acyclovir. Ann Intern Med 1983; 98:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/50\">",
"      Parker AC, Craig JI, Collins P, et al. Acyclovir-resistant herpes simplex virus infection due to altered DNA polymerase. Lancet 1987; 2:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/51\">",
"      Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003; 163:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/52\">",
"      Danve-Szatanek C, Aymard M, Thouvenot D, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004; 42:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/53\">",
"      Englund JA, Zimmerman ME, Swierkosz EM, et al. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med 1990; 112:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/32/7690/abstract/54\">",
"      Mertz GJ, Jones CC, Mills J, et al. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. JAMA 1988; 260:201.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8346 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.211.0.116-FDF613C4EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_32_7690=[""].join("\n");
var outline_f7_32_7690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H48\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Primary infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonprimary infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Recurrent symptomatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ANTIVIRAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT OF PRIMARY HSV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acyclovir versus placebo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Famciclovir versus acyclovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Valacyclovir versus acyclovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Valacyclovir versus famciclovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Complicated HSV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Adjunctive therapy for primary HSV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Timing of initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Summary for primary genital HSV treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT STRATEGIES FOR RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Therapeutic options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Comparisons between episodic and suppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Clinical benefits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Patient considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Frequency of recurrences",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Adherence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Psychosocial considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Cost of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Risk of transmission to uninfected partner",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      EPISODIC TREATMENT OF RECURRENT GENITAL HERPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Importance of timing of therapy for episodic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Acyclovir versus placebo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Famciclovir versus placebo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Valacyclovir versus placebo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Head-to-head comparisons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Treatment recommendations for episodic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUPPRESSIVE THERAPY FOR RECURRENT GENITAL HERPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Acyclovir versus placebo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Famciclovir versus placebo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Valacyclovir versus placebo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Head-to-head comparison trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Valacyclovir versus famciclovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Valacyclovir versus acyclovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Valacyclovir use in discordant couples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Treatment recommendations for suppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      CHRONIC SUPPRESSIVE THERAPY FOR DISCORDANT COUPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9186033\">",
"      SPECIAL CONSIDERATIONS IN HIV-INFECTED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      ANTIVIRAL DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9186078\">",
"      PATIENT COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15417?source=related_link\">",
"      Aseptic meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=related_link\">",
"      Foscarnet: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33001?source=related_link\">",
"      Genital herpes simplex virus infection and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/3/36916?source=related_link\">",
"      Patient information: Genital herpes (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=related_link\">",
"      Patient information: Genital herpes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21751?source=related_link\">",
"      Prevention of genital herpes virus infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_32_7691="Mimics of sepsis";
var content_f7_32_7691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Noninfectious mimics of sepsis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Acute myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute pulmonary embolus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fat emboli syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute adrenal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute gastrointestinal hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overzealous diuresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transfusion reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adverse drug reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Procedure-related transient bacteremia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amniotic fluid embolism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Cuhna, BA, Crit Care Clin 1998; 14:1",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_32_7691=[""].join("\n");
var outline_f7_32_7691=null;
var title_f7_32_7692="Complications of pulmonary AVMs";
var content_f7_32_7692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of pulmonary AVMs in all published series 1948-1999",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Range, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Respiratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asymptomatic",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        25 to 58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dyspnea",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        27 to 71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chest pain",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        6 to 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Haemoptysis",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        4 to 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Haemothorax",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        0 to 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyanosis",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        9 to 73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clubbing",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        6 to 68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bruit",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        25 to 58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Embolic phenomenon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerebral abscess",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0 to 25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CVA or TIA",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        11 to 55",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54:714.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_32_7692=[""].join("\n");
var outline_f7_32_7692=null;
var title_f7_32_7693="Predictive value TM exam";
var content_f7_32_7693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predictive value of combinations of otoscopic findings in children with acute ear symptoms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Position of TM",
"      </td>",
"      <td class=\"subtitle1\">",
"       Mobility of TM",
"      </td>",
"      <td class=\"subtitle1\">",
"       Color of TM",
"      </td>",
"      <td class=\"subtitle1\">",
"       Predictive value, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"       Combinations with &gt;80 percent predictive value of AOM compared with myringotomy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bulging",
"      </td>",
"      <td>",
"       Distinctly impaired",
"      </td>",
"      <td>",
"       Cloudy",
"      </td>",
"      <td>",
"       99",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bulging",
"      </td>",
"      <td>",
"       Slightly impaired",
"      </td>",
"      <td>",
"       Cloudy",
"      </td>",
"      <td>",
"       99",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bulging",
"      </td>",
"      <td>",
"       Distinctly impaired",
"      </td>",
"      <td>",
"       Distinctly red",
"      </td>",
"      <td>",
"       94",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bulging",
"      </td>",
"      <td>",
"       Slightly impaired",
"      </td>",
"      <td>",
"       Slightly red",
"      </td>",
"      <td>",
"       93",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bulging",
"      </td>",
"      <td>",
"       Distinctly impaired",
"      </td>",
"      <td>",
"       Slightly red",
"      </td>",
"      <td>",
"       85",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bulging",
"      </td>",
"      <td>",
"       Slightly impaired",
"      </td>",
"      <td>",
"       Distinctly red",
"      </td>",
"      <td>",
"       83",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Normal",
"      </td>",
"      <td>",
"       Distinctly impaired",
"      </td>",
"      <td>",
"       Cloudy",
"      </td>",
"      <td>",
"       97",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Normal",
"      </td>",
"      <td>",
"       Distinctly impaired",
"      </td>",
"      <td>",
"       Distinctly red",
"      </td>",
"      <td>",
"       89",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"       Combinations with &lt;50 percent predictive value of AOM compared with myringotomy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Normal",
"      </td>",
"      <td>",
"       Slightly impaired",
"      </td>",
"      <td>",
"       Distinctly red",
"      </td>",
"      <td>",
"       47",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Normal",
"      </td>",
"      <td>",
"       Slightly impaired",
"      </td>",
"      <td>",
"       Slightly red",
"      </td>",
"      <td>",
"       41",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Normal",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       Cloudy",
"      </td>",
"      <td>",
"       37",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Normal",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       Distinctly red",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Normal",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       Slightly red",
"      </td>",
"      <td>",
"       7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Normal",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       0.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Retracted",
"      </td>",
"      <td>",
"       Distinctly impaired",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       29",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Retracted",
"      </td>",
"      <td>",
"       Slightly impaired",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TM: tympanic membrane.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      Pelton, SI. Otoscopy for the diagnosis of otitis media. Pediatr Infect Dis J 1998; 17:540.",
"      <br>",
"       Karma, PH, Sipila, MM, Kayaja, MJ, Penttila, MA. Pneumatic otoscopy and otitis media: The value of different tympanic membrane findings and their combinations. In: Recent advances in otitis media: proceedings of the Fifth International Symposium, Lim, DJ, Bluestone, CD, Klein, JO, et al (Eds), Decker, Burlington, Ontario, Canada, 1993. p. 41.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_32_7693=[""].join("\n");
var outline_f7_32_7693=null;
var title_f7_32_7694="Natal cleft with pilonidal sinus";
var content_f7_32_7694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F87098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F87098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Natal cleft with pilonidal sinus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 305px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows several hair follicle pores in the natal cleft. A pilonidal sinus extends cephalad from the pores.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_32_7694=[""].join("\n");
var outline_f7_32_7694=null;
var title_f7_32_7695="Contents: Nutritional issues in children";
var content_f7_32_7695=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Nutritional issues in children",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Nutritional issues in children",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cystic fibrosis nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29095\">",
"           Cystic fibrosis: Assessment and management of pancreatic insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/24/15754\">",
"           Cystic fibrosis: Nutritional issues",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Food allergy and intolerance",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/52/34631\">",
"           Food protein-induced proctitis/colitis and enteropathy of infancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/32/5641\">",
"           Lactose intolerance",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Inflammatory bowel disease nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/7/24693\">",
"           Clinical manifestations of Crohn's disease in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/46/2794\">",
"           Growth failure and poor weight gain in children with inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/6/43113\">",
"           Nutrient deficiencies in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/47/41722\">",
"           Overview of the management of Crohn's disease in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/34/4650\">",
"           Treatment of ulcerative colitis in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Malnutrition in developing countries",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/31/32248\">",
"           Malnutrition in developing countries: Clinical assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/4/38983\">",
"           Micronutrient deficiencies associated with malnutrition in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/61/9178\">",
"           Severe malnutrition in children in developing countries: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Methods of nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/8/19593\">",
"           Approach to enteral nutrition in the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/39/42616\">",
"           Breastfeeding: Parental education and support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/16/11529\">",
"           Enteral nutrition in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/6/23655\">",
"           Human milk feeding and fortification of human milk for premature infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/47/32505\">",
"           Infant benefits of breastfeeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/28/458\">",
"           Nutritional composition of human milk and preterm formula for the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/36/6727\">",
"           Nutritional composition of human milk for full-term infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/1/32794\">",
"           Principles of medication use during lactation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/8/19593\">",
"           Approach to enteral nutrition in the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/7/27765\">",
"           Discharge planning for high-risk newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/60/27591\">",
"           Fluid and electrolyte therapy in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/22/23912\">",
"           Growth management in preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/50/27434\">",
"           Parenteral nutrition in premature infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutritional assessment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/61/28631\">",
"           Dietary history and recommended dietary intake in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/22/23912\">",
"           Growth management in preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/40/36487\">",
"           Indications for nutritional assessment in childhood",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/55/22391\">",
"           Laboratory and radiologic evaluation of nutritional status in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/38/6760\">",
"           Measurement of body composition in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/14/31976\">",
"           Measurement of growth in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/4/38983\">",
"           Micronutrient deficiencies associated with malnutrition in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutritional deficiencies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/12/14538\">",
"           Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/18/22826\">",
"           Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/2/38949\">",
"           Iron deficiency in infants and young children: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4329\">",
"           Iron requirements and iron deficiency in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/14/23782\">",
"           Physiology of vitamin B12 and folate deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/3/29753\">",
"           Zinc deficiency and supplementation in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutritional requirements",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/8/19593\">",
"           Approach to enteral nutrition in the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/6/40040\">",
"           Calcium requirements in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/11/23735\">",
"           Dietary energy requirements in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/6/23655\">",
"           Human milk feeding and fortification of human milk for premature infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/18/22826\">",
"           Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/2/38949\">",
"           Iron deficiency in infants and young children: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4329\">",
"           Iron requirements and iron deficiency in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9462\">",
"           Metabolism of vitamin D",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/59/37816\">",
"           Neonatal hyperglycemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/28/458\">",
"           Nutritional composition of human milk and preterm formula for the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/19/39226\">",
"           Overview of dietary trace minerals",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/14/21736\">",
"           Overview of vitamin A",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/3/39990\">",
"           Overview of vitamin D",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/12/28871\">",
"           Overview of vitamin E",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/37/15960\">",
"           Overview of vitamin K",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/62/28650\">",
"           Overview of water-soluble vitamins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/38/28266\">",
"           Vitamin D insufficiency and deficiency in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Obesity",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/11/8378\">",
"           Clinical evaluation of the obese child and adolescent",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/50/37674\">",
"           Comorbidities and complications of obesity in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/5/32858\">",
"           Definition; epidemiology; and etiology of obesity in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/60/18378\">",
"           Management of childhood obesity in the primary care setting",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Short bowel syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/45/29400\">",
"           Chronic complications of the short bowel syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/9/26778\">",
"           Management of the short bowel syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/56/30601\">",
"           Pathophysiology of the short bowel syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Specific diets",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/24/16778\">",
"           Adolescent eating habits",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/61/42967\">",
"           Fast food for children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/9/9369\">",
"           Organic foods and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/4/8266\">",
"           Vegetarian diets for children",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-E9C98EF43E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f7_32_7695=[""].join("\n");
var outline_f7_32_7695=null;
